Conditions: P Vivax Malaria, Vivax
Keywords: treatment response efficacy primaquine chloroquine
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 257
Healthy volunteers: no

Brief summary:
We plan to assess the efficacy of 3 different regimens of chloroquine and primaquine for the treatment of P. vivax infections in Cruzeiro do Sul, Acre, Brazil. Patients will be divided in 3 different groups: treatment with regular dose of primaquine (0.5 mg/kg per day for 7 days) with directly observed therapy; regular dose of primaquine without directly observed therapy; and increased total dose of primaquine (0.5 mg/kg per day for14 days) with directly observed therapy. All patients will receive chloroquine (CQ) for three days at a daily dose of approximately 25 mg/Kg in accordance with the Brazilian National Malaria Control guidelines. Clinical and parasitologic parameters will be monitored over a 28-day follow-up period to evaluate drug efficacy and for a total period of 168 days (24 weeks) to evaluate chances of recrudescence, relapse, or reinfection. Results from this drug efficacy study will be used to assist the Brazilian Ministry of Health in assessing their national malaria treatment policy for P. vivax malaria.

Detailed description:
Background: The World Health Organization recommends that antimalarial treatment policies be evaluated every few years to check their efficacy. P. vivax malaria is the most common species in Brazil and cases are concentrated in the Amazon Region in Brazil.

Objectives: Assess the efficacy of 3 different regimens of chloroquine and primaquine for the treatment of P. vivax infections in Cruzeiro do Sul, Acre, Brazil.

Methods: An in vivo drug efficacy study will be conducted in Cruzeiro do Sul, Acre State, Brazil. A total of 257 study participants ≥5 years of age with parasitologically confirmed P. vivax monoinfections will be included. Patients will be divided in 3 different groups: treatment with regular dose of primaquine (0.5 mg/kg per day for 7 days) with directly observed therapy; regular dose of primaquine without directly observed therapy; and increased total dose of primaquine (0.5 mg/kg per day for14 days) with directly observed therapy. All patients will receive chloroquine (CQ) for three days at a daily dose of approximately 25 mg/Kg in accordance with the Brazilian National Malaria Control guidelines. Primaquine will be given for 7 or 14 days under supervision or not, depending on the study group. Clinical and parasitologic parameters will be monitored over a 28-day follow-up period to evaluate drug efficacy and for a total period of 168 days (24 weeks) to evaluate chances of recrudescence, relapse, or reinfection. Blood samples will be taken to measure the CQ levels in blood on Day 7 and day of failure, if occurring in the initial 28 days of follow up. In addition, a blood sample will be collected on filter paper on first day and on day of suspected failure to help differentiate parasite genotypes using techniques based on polymerase chain reaction. Results from this drug efficacy study will be used to assist the Brazilian Ministry of Health in assessing their national malaria treatment policy for P. vivax malaria.

Arms:
arm 1: This is the regular primaquine dose Brazil without directly observed therapy. arm 2: This is the regular primaquine dose in Brazil but with directly observed therapy. arm 3: This is the double total primaquine dose (14 days) in Brazil with directly observed therapy.

Interventions: intervention 1: Primaquine
Intervention descriptions: intervention 1: Different total dose and supervision.

Protocol document:
Prot_SAP_ICF_000.pdf: 
1 
 
 
Protocol  
 
 
Efficacy of High Total Dose of Primaquine to Prevent Plasmodium vivax Malaria Relapses in Cruzeiro 
do Sul, Brazil  
 
Approved by CDC IBR on Dec 20, 2017  
 
Investigator(s) and Institutions  
• Nathália N. Chamma Siqueira, MSc, Instituto Evandro Chagas, Brazil.  Mrs. Chamma will be 
responsible for laboratory processing; data analysis; and coordinating manuscript writing.  She will 
be also responsible for leading manuscript review, updating and making changes to final manuscript; 
and for active engagement with partner institutions.  
• Dr. Suiane Negreiros do Valle, MD, PhD, Health Secretariat of Acre State (Hospital Regional do 
Jurua).  Dr. Negreiros will be responsible for implementation; support for data cleaning and analysis; 
interactions with public health authorities in Brazil; ethical review process in Brazil; manuscript 
writing; and general oversight of the study.   
• Sarah-Blythe Ballard, MD, PhD, MPH, Malaria Branch, CDC (SEV 7105). Dr. Ballard will be 
responsible for technical assistance to the protocol and project implementation.  Dr. Ballard will 
likely interact with study subjects at the time of study implementation and supervisory visits.  She 
will not have access to stored personal identifiers.   
• Samela Farias, nurse, specialist, Health Secretariat of Acre State (Hospital Regional do Jurua). Mrs. 
Farias will be responsible data collection, day-to-day management of study staff, leading the team of 
nurses, nurse assistants and microscopists involved in data collection; direct contact with participants 
for data collection; critical review and refinement of enrollment and follow-up standard operating 
procedures (SOPs); data cleaning; provision of answers to queries from CDC during data collection, 
data analysis, and paper writing; coordination of sample shipment.  
• Sandro Patroca da Silva, PhD, Instituto Evandro Chagas. Dr Silva will be responsible for issues 
related to microsatellites laboratory testing, including bench work itself, result gathering, dataset 
generation, data interpretation, and manuscript writing.  
• Stella M. Chenet, PhD, Universidad Nacional Toribio Rodriguez de Mendonza da Amazonas. Dr. 
Chenet will be responsible for issues related to microsatellites laboratory testing, from conception, 
decision on testing algorithms, analysis and interpretation, and manuscript writing.  


2 
 
 
• Flávia Póvoa da Costa, MSc, Instituto Evandro Chagas.  Mrs. Costa will be responsible for issues 
related to CYP2D6 laboratory bench work itself, result gathering, dataset generation, and providing 
technical input to manuscript.  
• Luann Wendel Pereira Sena, PhD, Universidade Federal do Pará. Dr. Sena will be responsible for 
CYP2D6 laboratory testing, including conception, laboratory bench work itself, data interpretation, 
and providing technical input to manuscript.  
• Amanda Gabryelle Nunes Cardoso, PhD, Universidade Federal do Pará. Dr. Cardoso will be 
responsible for CYP2D6 laboratory testing, including algorithms testing, data interpretation, and 
providing technical input to manuscript.  
• Eduardo Santos, PhD, Universidade Federal do Pará. Dr. Santos will be responsible for issues related 
to CYP2D6 laboratory testing including conception, decision on testing algorithms, data analysis and 
interpretation, and providing technical input to manuscript.  
• Giselle Rachid Viana, PhD, Instituto Evandro Chagas.  Dr. Viana will be responsible for study 
planning, review of all laboratory tests, quality assurance and control or laboratory procedures used 
in this study, and critical review of manuscript.   
• Paola Marchesini, MD, PhD, Grupo Técnico de Malária, Coordenação Geral de Vigilância de 
Zoonoses e Doenças de Transmissão Vetorial, Departamento de Imunização e Doenças 
Transmissíveis, Secretaria de Vigilância em Saúde (SVS), Ministério da Saúde do Brasil.  Dr. 
Marchesini will be responsible for overall project, making sure it fits into the needs of the national 
malaria control program in Brazil, and manuscript writing.   
• Cássio Roberto Leonel Peterka, MSc., Diretoria de Vigilância Epidemiológica, Subsecretaria de 
Vigilância em Saúde, Secretaria Estadual de Saúde do Distrito Federal, Brasília, Distrito Federal, 
Brazil. Mr Peterka will be responsible for overall project, making sure it fits into the needs of the 
national malaria control program in Brazil, and critical review of manuscript.   
• Marinete Marins Povoa PhD, Instituto Evandro Chagas.  Dr. Povoa will be responsible for 
supervising all laboratory procedures associated with this project.   
• Venkatachalam (Kumar) Udhayakumar, PhD, Malaria Branch, CDC (IRB number 13427).  Dr. 
Kumar will be responsible for supervising and troubleshooting the molecular typing to be done as 
part of this study.  He will not have access to any personal identifier.   
• Michael Green, PhD, Entomology, CDC (IRB number 17614).  Dr. Green will be responsible for 
supervising and troubleshooting the antimalarial blood level determination to be done as part of this 
study.  He will not have access to any personal identifier.   


3 
 
 
• Alexandre Macedo de Oliveira, MD, MSc, PhD, Malaria Branch, CDC (IRB number 9885).  Dr. 
Macedo de Oliveira will be responsible for technical assistance to the protocol development, 
implementation, supervision of field work; coordination of data cleaning and analysis, interactions 
with all subject matter experts; manuscript writing and review; and coordination between colleagues 
in Brazil and at CDC.  Dr. Macedo de Oliveira will likely interact with study subjects at the time of 
study implementation and supervisory visits.  He will not have access to stored personal identifiers.   
 
 
Conflict of interest  
None of the authors have any conflict of interest to report.   
 


4 
 
 
Table of Contents  
 
Summary 
 
 
 
 
 
 
 
 
 
 
 
6 
Background 
 
 
 
 
 
 
 
 
 
 
 
7 
Objectives 
 
 
 
 
 
 
 
 
 
 
 
11 
Methods 
 
 
 
 
 
 
 
 
 
 
 
11 
Study site ................................................................................................................................... 11 
Timing of study ......................................................................................................................... 12 
Study teams ............................................................................................................................... 12 
Groups of study ......................................................................................................................... 12 
Study procedures ....................................................................................................................... 12 
Inclusion criteria ........................................................................................................................ 14 
Exclusion criteria ....................................................................................................................... 15 
Sample size ................................................................................................................................ 16 
Pregnancy testing ....................................................................................................................... 18 
Enrollment procedures ............................................................................................................... 18 
Schedule of study procedures .................................................................................................... 20 
Blood smear ............................................................................................................................... 22 
Antimalarial therapy .................................................................................................................. 22 
Concomitant treatment .............................................................................................................. 27 
Follow-up procedures ................................................................................................................ 27 
Chloroquine blood levels ........................................................................................................... 28 
Molecular analysis ..................................................................................................................... 28 
Microsatellite genotyping .......................................................................................................... 28 
Outcome measures ..................................................................................................................... 29 
Loss to follow-up ....................................................................................................................... 31 
Withdrawal from study .............................................................................................................. 31 
Participation interruption ........................................................................................................... 31 
Adverse events ........................................................................................................................... 32 
Alternative treatment ................................................................................................................. 33 
Limitations 
 
 
 
 
 
 
 
 
 
 
 
33 
Ethical considerations  
 
 
 
 
 
 
 
 
 
33 
Data management 
 
 
 
 
 
 
 
 
 
 
35 
Statistical analysis 
 
 
 
 
 
 
 
 
 
 
35 
Dissemination of results 
 
 
 
 
 
 
 
 
 
36 
Budget  
 
 
 
 
 
 
 
 
 
 
 
36 
References 
 
 
 
 
 
 
 
 
 
 
 
38 
Appendix A1: Consent Form. Informed Consent Form for Patients Aged 18 years and older.  (Flesh-Kincaid 
7.6) 
 
 
 
 
 
 
 
 
 
 
 
 
40 
Appendix A2: Parental Permission Form for Parents of Patients Aged 5 Through 17 years.  (Flesh-Kincaid 
7.6) 
 
 
 
 
 
 
 
 
 
 
 
 
47 
Appendix B1: Assent Form (for participants aged 7–12, inclusive) (Flesh-Kincaid 3.8) 
 
54 
Appendix B2:  Assent Form (for participants aged 13–17, inclusive) (Flesh-Kincaid 4.6)  
55 
Annex C1. Authorization for storage of remaining samples (Participants aged 18 years and older and Parents 
of Participants aged five through 17 years) (Flesh-Kinkaid level 7.6) 
 
 
 
57 
Annex C2. Assent Form for Storage of Remaining Samples (Participants 7 to 12 years) 
 
60 
Annex C3. Assent Form for Storage of Remaining Samples (Participants 13 to 17 years)  
61 
Annex D. Antimalarial drugs that should not be used in the 30 days prior to enrolment and also during the 
study period  
 
 
 
 
 
 
 
 
 
 
62 


5 
 
 
Annex E: Patient form 
 
 
 
 
 
 
 
 
 
63 
Annex G. Randomization table. 
 
 
 
 
 
 
 
 
113 
 
 


6 
 
 
Summary  
Background:  The World Health Organization recommends that antimalarial treatment policies be evaluated 
every few years to check their efficacy.  P. vivax malaria is the most common species in Brazil and cases are 
concentrated in the Amazon Region in Brazil.   
Objectives:  Assess the efficacy of 3 different regimens of chloroquine and primaquine for the treatment of 
P. vivax infections in Cruzeiro do Sul, Acre, Brazil.  
Methods: An in vivo drug efficacy study will be conducted in Cruzeiro do Sul, Acre State, Brazil.  A total of 
257 study participants ≥5 years of age with parasitologically confirmed P. vivax monoinfections should be 
included.  Patients will be divided in 3 different groups: treatment with regular dose of primaquine (0.5 
mg/kg per day for 7 days) with directly observed therapy; regular dose of primaquine without directly 
observed therapy; and increased total dose of primaquine (0.5 mg/kg per day for14 days) with directly 
observed therapy.  All patients will receive chloroquine (CQ) for three days at a daily dose of approximately 
25 mg/Kg in accordance with the Brazilian National Malaria Control guidelines.  Primaquine will be given 
for 7 or 14 days under supervision or not, depending on the study group.  Clinical and parasitological 
parameters will be monitored over a 28-day follow-up period to evaluate drug efficacy and for a total period 
of 168 days (24 weeks) to evaluate chances of recrudescence, relapse, or reinfection.  Blood samples will be 
taken to measure the CQ levels in blood on Day 7 and day of failure, if occurring in the initial 28 days of 
follow up.  In addition, a blood sample will be collected on filter paper on first day and on day of suspected 
failure to help differentiate parasite genotypes using techniques based on polymerase chain reaction. We also 
intent to analyze CYP2D6 gene polymorphisms and correlated those to metabolic activity phenotypes to 
correlate them with treatment response. Results from this drug efficacy study will be used to assist the 
Brazilian Ministry of Health in assessing their national malaria treatment policy for P. vivax malaria.  
 
 


7 
 
 
Background  
The impact of malaria on the health and economic development of human populations is greatest in the 
tropics and subtropics.  The World Health Organization (WHO) has estimated 212 million episodes of 
malaria in 2015, of which 90% of those in in Africa.  There were a total of 429,000 malaria deaths 
worldwide, the majority in in children under 5 years of age (WHO 2015).  Although the majority of deaths 
occur among children in sub-Saharan Africa, malaria accounts for considerable morbidity in the Americas, 
particularly in the Amazon Basin.   
 
Most countries in the Americas have adopted the WHO Global Strategy for Malaria Control, which relies on 
prompt and effective antimalarial treatment as the major means of reducing malaria morbidity and mortality 
(WHO 2008).  The ultimate success of this strategy rests on the ability of ministries of health to provide 
antimalarial drugs with proven efficacy.  Although a wide variety of methods have been used to assess 
resistance to antimalarial drugs in vivo methods, in vitro drug sensitivity testing, and molecular analyses, 
most national malaria control programs rely on data from in vivo efficacy trials to assess the efficacy of the 
current first- and second-line drugs and to decide if charges in malaria treatment policy are needed.   
 
The most widely used approach to conduct in vivo drug efficacy trials in the Americas follows the guidelines 
of the WHO (WHO 2009, WHO 2015) with the modifications recommended by the Pan American Health 
Organization for studies in the Americas (PAHO 2003).  The goal of such studies is to assess antimalarial 
drugs currently being used for first-line treatment of uncomplicated malaria.  Much of the effort to monitor 
antimalarial efficacy in the Americas has been done as part of the Amazon Network of Antimalarial 
Resistance Monitoring and the Amazon Malaria Initiative (PAHO 2012).  This information is critical for 
guiding the development of rational antimalarial drug policies in endemic areas.   
 
Chloroquine-resistant P. vivax was first reported from Papua New Guinea in 1989 in two Australian soldiers 
(Rieckmann, Davis et al. 1989).  In 1995, a study in Irian Jaya, Indonesia showed resistance in at least 44% 
of the P. vivax patients treated with chloroquine (CQ) (Baird, Basri et al. 1995).  Several investigators have 
reported cases of CQ-resistant P. vivax in South America.  In 1996, in Guyana, Phillips et al. reported three 
patients in whom 25 mg/kg of CQ failed to eliminate parasitemia despite adequate therapeutic blood levels 
of CQ (Phillips, Keystone et al. 1996).  Three years later, in the Brazilian Amazon region, Alecrim et al. 
reported a 12-year old girl with P. vivax malaria who continued to have parasitemia after receiving a 
supervised course of 25mg/kg of CQ (Alecrim, Alecrim et al. 1999).  More recently, Soto et al. reported 
three cases of CQ-resistant P. vivax in Colombia (Soto, Toledo et al. 2001).   


8 
 
 
 
In addition, recent studies have shown high reinfection rates by P. vivax even after treatment with 
recommended dose of primaquine (0.5 mg/kg per day for 7 days)  (Durand, Cabezas et al. 2014, Negreiros, 
Farias et al. 2016).  Despite the fact that primaquine is the only drug currently available for the terminal 
treatment of P. vivax and P. ovale infections, variable reinfection rates have been reported in the literature 
(Hill, Baird et al. 2006, Durand, Cabezas et al. 2014).  WHO recommends daily dose of 0.25 mg/kg/day 
(infections from temperate regions) and 0.50 mg/kg/day (infections from tropical regions with high rates of 
relapses) all over 14 days, with a total dose of 3.5 mg/kg or 7.0 mg/kg, respectively, after reports of relapses 
in Asia and Oceania (Collins and Jeffery 1996, Baird and Hoffman 2004, WHO 2015).  This concern about 
frequent relapses has led CDC to change its recommendation to increase the total dose of primaquine for 
terminal treatment 7.0 mg/kg to be given over 14 days for terminal treatment for P. vivax infections from all 
regions of the world (Centers for Disease Control and Prevention 2015).    
 
Because of the serious public health implications of CQ-resistant and primaquine-resistant P. vivax in the 
Americas, it is critically important to limit reports to well-confirmed cases.  In most cases, this will require 
measurement of CQ blood levels and genotyping of parasites from the initial infection and any suspected 
recrudescence.  P. falciparum in vivo trials take advantage of well-established molecular markers that help 
differentiate cases of recrudescence and reinfection, by polymerase chain reaction (PCR) techniques.  
Although no universally accepted technique for this purpose exists for P. vivax.  Microsatellites, base pair 
repeats in the parasite genome, described by Imwong et al (Imwong, Sudimack et al. 2006) have been used 
for this purpose with variable results.  We believe that having PCR-corrected analysis is especially important 
in the context of the long follow-up period, six months, we aim for this study.   
 
Most malaria cases in the Americas are reported in Brazil (Silveira 2001, Oliveira-Ferreira, Lacerda et al. 
2010).  In 2016, 151,620 malaria cases were reported to the Brazilian National Reportable Disease 
Information System.  Most of these cases (99.7%) occurred in the Amazon region, which encompasses the 
states of Acre, Amazonas, Amapa, Para, Maranhao, Mato Grosso, Roraima, Rondonia, and Tocantins.  In 
this region, socio-economic and environmental conditions, such as presence of natural breeding sites and 
abundance of Anopheles mosquitoes, favor malaria transmission.  Amazonas, Rondonia, Para, and Acre 
states were responsible for 85.5% of malaria cases in 2011 according to the Brazilian National Reportable 
Disease Information System.  As in other regions of the world, malaria is seasonal in Brazil, cases increase 
during or after the rainy season (Costa 2009).   
 


9 
 
 
In 2016, 73.9% of malaria cases in Brazil were due to P. vivax alone, 9.47% to P. falciparum alone, and the 
rest due to mixed infections with these two species.  P. malariae is rarely seen in Brazil (regular surveillance 
data from Brazil, SIVEP, 2017).  Table 1 shows malaria cases over the last few years.     
 
Acre state is responsible for a huge proportion of cases in the Brazilian Amazon region, especially in the 
municipalities of Cruzeiro do Sul, Mâncio Lima and Rodrigues Alves (Figure 1).  In 2016, Acre had 35,209 
cases in addition to 4,098 positive cases detected during treatment response control slides (TRCS), a total of 
39,307.  Cruzeiro do Sul had 20,591 cases, with additional 2,195 cases by TRCS, a total of 22,786 cases 
(data from the Brazilian National Surveillance System, 2017).  
 
 
 


10 
 
 
Table 1. Malaria cases in Brazil.    
Region 
2012 
2013 
2014 
2015 
2016 
Cases 
Cases 
Cases 
Cases 
Cases 
Brazil  
234,545 
169,231 
138,936 
137,947 
123,935 
North  
234,497 
169,187 
13,8919 
137,925 
123,904 
Acre  
27,005 
33,755 
30,982 
26,632 
34,382 
Cruzeiro 
do Sul  
16,053 
19,701 
17,179 
13,936 
19,027 
 
 
Figure 1.  Acre state and malaria risk by region, 2008.   
 
 
Source: Acre state Health Secretariat.   
Legend: Alto Risco, High risk; Medio Risco, Medium risk, and Baixo Risco, Low risk.   
 
 
 


11 
 
 
Although currently there is no evidence of CQ-resistant or primaquine-resistant P. vivax in Cruzeiro do Sul, 
Acre State, Brazil, there is concern about the tolerance to primaquine.  The Ministry of Health would like to 
assess the efficacy of three regimens of CQ and primaquine for the treatment of uncomplicated P. vivax 
malaria as part their effort to study antimalarial drug resistance within the country.   
 
Objectives  
The objective of this study is to evaluate the therapeutic efficacy of CQ and primaquine in the treatment of P. 
vivax malaria in Cruzeiro do Sul, State of Acre, Brazil using three primaquine schemes. These are (1) routine 
standard dose in Brazil, WHO dose for temperate regions with supervised treatment; (2) double dose, WHO 
dose recommended for tropical regions with supervised treatment, and (3) standard dose treatment from 
Brazil without supervision.   
 
Methods 
Study site  
This study will take place at the malaria treatment posts in Cruzeiro do Sul, Acre State, Brazil.  Cruzeiro do 
Sul is a municipality with 85,000 residents in Northwest Brazil.  Both P. vivax and P. falciparum malaria are 
endemic in the region with an annual parasite incidence (API) of 233.4/1,000 (data from the Brazilian 
National Surveillance System, 2017).  In accordance to Brazilian national policies, malaria diagnosis and 
treatment are offered free of charge in the region.  Road access to public health facilities is relatively easy in 
the urban and peri urban areas of the city.  It is common practice in this region for patients to present to 
health facilities for diagnosis and first treatment dose.  Patients could be then visited at home by health 
agents for directly observed therapy of the following doses.   
 
The study will take place with patients recruited on spontaneous demand who attend the Emergency Room 
of the Juruá Regional Hospital (HRJ). This malaria post has a malaria diagnostic laboratory running 24 hours 
continuously, and it also registers the highest number of malaria cases in the city, according to statistics from 
the Brazilian malaria information system (SIVEP).Seven other malaria diagnostic stations will also be 
selected for this study, health posts located in the neighborhoods of Aeroporto Velho, Miritizal, Cruzeirinho, 
and others, and will be coordinated by the mobile team of the study.  After the period of recruiting patients, 
the teams will be installed in the Clinical Research Room located at Santa Casa de Misericórdia de Cruzeiro 
do Sul.   
 


12 
 
 
Timing of study  
The study will be conducted from during malaria transmission season, ideally from February 2018 to 
December 2018.  Close communication will be maintained with regional and local health officials to 
determine the most appropriate time for the study to begin.  Due to the 6-month follow-up period (168 days), 
we expect to conclude patient follow-up by December 2018 and data analysis by May 2019.    
 
Study teams  
At least two clinical teams will be required to conduct this study and interact with patients. Each team will 
consist of a nurse and a nursing assistant.  One team will be based in the HRJ outpatient clinic and the other 
in the malaria research room.  The team based in the clinical research room will be a mobile team 
responsible for admitting and following patients at least three malaria diagnostic post that are not at the HRJ 
(Cruzeirinho, Aeroporto Velho, Miritizal, and others).  In addition to the clinical teams, one supervising 
physician and three microscopists will be part of the study.   
 
Groups of study 
This evaluation will have three distinct patient groups:  
1. Group 1. Treatment with supervised CQ and unsupervised primaquine with usual primaquine dose of 
3.5 mg/kg (0.50 mg/kg / day for 7 days).  
2. Group 2. Treatments with CQ and primaquine supervised with usual primaquine dose of 3.5 mg/kg 
(0.50 mg/kg/day for 7 days).  
3. Group 3. Treatments with supervised CQ and primaquine with increased primaquine total dose of 7.0 
mg/kg (0.50 mg/kg/day for 14 days).  
 
Group 3 will be the comparison group for efficacy and reinfection at the 24-week follow-up. Treatment 
response rates at Day 28 and during complete follow-up for reinfections will be compared between Groups 1 
and 3, and between Groups 2 and 3.   
 
Study procedures  
The physician will act as study coordinator and will be responsible for overall study supervision, study 
forms, and administrative issues. The study doctor will supervise the entire clinical staff at all times and will 
be available to handle unexpected events.  
 


13 
 
 
The nurse will be responsible for evaluating the patients at the time of admission to the study, obtaining a 
clinical history, conducting a physical examination, administering the study medication (CQ and primaquine 
after confirmation of normal levels of glucose-6-phosphate dehydrogenase activity [G6PD]), visits on the 
first four days of follow-up (Days 0, 1, 2, and 3) and preferably Day 7, either in the study centers or at home 
visits (see below).   
 
The nursing assistant will be responsible for monitoring primaquine doses for 7 or 14 days (after 
confirmation of normal levels of G6PD activity) depending on the study group, through visits to the patients 
at their homes for follow-up visits and patients' remaining check-ups. Since primaquine therapy can only be 
started after confirmation of normal G6PD activity, this drug will not be initiated on Day 0 when CQ will be 
initiated.  We expect to have G6PD results within one week; therefore, primaquine will likely be initiated 
during the first week of follow-up.  The doses of medicament, CQ and primaquine, will be administered with 
direct supervision, either by the nurse or by the nursing assistant, the two supervised treatment groups.  In the 
unsupervised primaquine treatment group, only the doses of CQ will be supervised. Both the nurse and the 
nursing assistant can collect the blood samples, via fingerprick and venous puncture, recommended with part 
of this study.   
 
As a routine practice in Ministry of Health facilities in Brazil, all febrile patients have a thick blood smear or 
rapid diagnostic test (RDT) for malaria examined before antimalarial treatment is administered.  This usually 
takes place at a health facility where sick patients present.  The staff of these malaria diagnostic posts, 
hospital and other health centers, will be informed of the study.  Patients attending the study sites, HRJ or the 
health posts, who have a positive blood smear or RDT for P. vivax will be approached by a member of the 
study team or told by a health facility staff about this in vivo trial.   
 
The study team nurse will assess inclusion and exclusion criteria and explain details about the study.  If 
eligible patients agree to take part in the study, they, or the patient’s parent (in case of patient’s age < 18 
years), will be asked to sign the informed consent or parental permission form (and also obtain verbal assent 
from children 7 through 17 years of age).  After that, patient will be undergo blood collection for malaria 
diagnosis confirmation, medical evaluation, and all other study procedures.  In case of refusal, patients will 
be referred back to health facility staff to receive the standard treatment for P. vivax malaria without any sort 
of penalty.   
 


14 
 
 
Enrolled patients will be asked to complete the CQ treatment at the health facility they were admitted at if 
they can.  The study team nurse will schedule home visits for those patients who do not wish to come back to 
the health facility for follow-up during the period the patient is receiving CQ.  Once a normal activity level 
of G6PD is documented, primaquine will be initiated and give also as supervised or not supervised doses, 
depending of the study group.  On and after Day 3, when CQ treatment ends, arrangements will be made 
with the patient to be seen at home.  The nurse assistant will make arrangements to visit patients at home for 
the remaining doses of primaquine.  Study team will encourage patients to come back to health facilities, but 
we expect that most patients will prefer to be visited at home as this is common practice in Cruzeiro do Sul 
for malaria treatment and follow-up.   
 
We believe that after CQ treatment is over and patient’s health status has improved, the study team nurse 
assistant will be able to appropriately manage the follow-up visits.  These nurse assistants will be in close 
contact with the nurse of their respective team and arrangements for re-evaluations will be made if necessary.    
 
Study microscopists will be responsible for reporting blood smears results on the same day they are taken.  
Details on how the laboratory work will be organized are provided below.  The physician will serve as a 
study coordinator, being responsible for the overall supervision of the study, study forms, and administrative 
issues.  All study team personnel will be trained in their respective tasks before the start of this study.  This 
training will take part in a 5-day period with participation of collaborators from the Centers for Disease 
Control and Prevention (CDC), Atlanta and Instituto Evandro Chagas, de Belem, Para.  We will also invite 
the Unidade De Boas Praticas Clinicas da Fiocruz (Good Clinical Practices Unit at Fiocruz) to take part in 
the study.   
 
In order to avoid reinfection due to malaria during the follow-up period, we will instruct patients to use 
malaria prevention measures. These are long-lasting insecticide-impregnated mosquito nets (ITNs).   
 
Inclusion criteria  
1. Age ≥5 years  
2. Body weight <120 kg  
3. Documented fever (axillary temperature ≥37.5o C) or history of fever during the previous 48 hours in 
the absence of another obvious cause of fever, such as pneumonia, otitis media, etc  
4. Monoinfection with P. vivax with parasitemia between 100 and 200,000 asexual parasites/µl as 
determined by microscopic examination of thick and thin peripheral blood smears  


15 
 
 
5. Informed consent from the patient or parent/guardian (for those <18 years), assent from child (ages 7 
to 17 years inclusive), patients 5 through 6 years old will not need an assent  
6. Willingness on the part of the patient to return to the clinic and/or receive home visits for regular 
check-ups during the 24-week (168 days) follow-up period 
7. Place of residence within 30–45 minutes of study site.    
 
Exclusion criteria 
1. Presence of malaria danger signs  
a. Unable to drink  
b. Vomiting (more than twice in the previous 24 hours)  
c. Recent history of convulsions (one or more in the previous 24 hours)  
d. Impaired consciousness  
e. Unable to sit or stand  
2. Presence of signs of severe malaria (WHO criteria)  
a. Cerebral malaria (unarousable coma)  
b. Severe anemia (hematocrit <15% or clinical signs) hemoglobin <5 mg/ml) (Note: we will use 
hemoglobin less than 8 mg/ml as exclusion criteria)   
c. Renal failure (serum creatinine >3 mg/dL or clinical signs)  
d. Pulmonary edema  
e. Hypoglycemia (blood glucose <40mg/dL or clinical signs)  
f. Shock (systolic blood pressure <70 mm Hg in adults; 50 mm Hg in children)  
g. Spontaneous bleeding/disseminate intravascular coagulation  
h. Repeated generalized convulsions  
i. Acidemia/acidosis (clinical signs)  
j. Macroscopic hemoglobinuria  
k. Jaundice  
3. Self-reported presence of other underlying chronic or severe diseases (e.g., cardiac, renal, hepatic 
diseases, HIV/AIDS, tuberculosis, malnutrition, psoriasis)  
4. History of hypersensitivity reactions to any of the drugs being tested.  Mild itching with CQ is not in 
itself a criterion for exclusion.  This occurrence will be evaluated by the study doctor before 
excluding the patient for this reason alone.   
5. Use of drugs with antimalarial activity in the past 30 days. (Annex D)  


16 
 
 
6. Current pregnancy (either self-reported being pregnant at enrollment or a positive urine or plasma 
pregnancy test at time of enrollment), previous pregnancy is not an exclusion criteria  
7. Hemoglobin <8 mg/mL  
8. G6PD deficiency.  This will be a late exclusion criteria as soon as the results of G6PD testing 
becomes available.   
 
Sample size  
Sample size was calculated based on the expected proportion of recurrent infection after treatment of P. 
vivax with CQ and primaquine in the study population. A previous study in Cruzeiro do Sul showed a 
recurrent infection rate of P. vivax at a 6-month follow-up of 30% and prevalence of heterologous isolates, 
reinfection or relapse by different genotype, from 16.6% of cases.(Negreiros, Farias et al. 2016) We estimate 
that the rate of recurrent infection after a double dose of primaquine (Group 3) is lower than that of 16.6% 
(most hypnozoites will be treated at the highest dose), and we estimate the recurrent infection rate in the dose 
group usual and supervised (Group 2) similar to that found by Negreiros and collaborators (30%). For Group 
1, based on discussions with Brazilian Ministry of Health, we estimated that, due to the adherence of 
patients, this will be 40%, higher than that of Group 2. 
 
Considering the above estimates and using Fisher Exact test, we needed 74 patients in each group to compare 
prevalence of 10% (Group 3) and 30% (Group 2) (power = 90% and 5% level of significance). Likewise, in 
order to compare difference of 10% (Group 3) and 40% (Group 1), we need 39 patients in each group.  
Increasing this minimum sample to 50 patients, which is recommended by the WHO as a minimum sample 
size for in vivo studies (WHO, 2009 # 40), and adding 30% in all groups to accommodate follow-up losses, 
we have sample size of 96 patients in Groups 2 and 3, and 65 patients in Group 1. The total number of 
patients in the study was 257 patients.   
 
Informed consent  
Informed consent, parental permission forms (TCLE in Portuguese acronym) and assents (TALE in 
Portuguese consent) are ways in which the participant confirms his or her participation in a clinical study. 
The TCLE (Appendices A1) is applicable for participants 18 years of age and older. In the case of 
participants less than age 18, the legal guardian must sign the TCLE for Parents or Legal Entities (Appendix 
A2), which serves as parental permission.  Oral assent participants aged 7 to 17, inclusive, years will be used 
(Appendices B1 and B2).  In the case of participants less than 18 years old at time of enrolment but who turn 


17 
 
 
18 during follow-up, we will request informed consent (TCLE) at his/her following visit after the 18th 
birthday.  If patient denies written consent, we will withdrawal him/her at that point.   
 
The objectives and procedures of the study and the rights of volunteers will be explained in detail to potential 
volunteers in Portuguese. The TCLE (Appendix A1) signed with a blue or black in three copies will be 
requested from all participants older than 18 years.  Permission using the same forms (Appendix A2) will be 
asked from guardians of participants younger than 18 years of age who are willing to participate.  A member 
of the study team should also sign this document.  In addition, a TALE (Appendices B1 and B2) will be 
requested orally from patients 7–17, inclusive, years of age, according to the participant's age range.  The 
practice of oral assent rather than its signature is due to the fact that the Ethics Committee of Brazil prefers 
only one document signed as part of the consent and consent process.  Assent will not be required from 
patients 5 to 6, inclusive, years of age. These documents will be applied by the principal investigator or 
someone trained by him/her.   
 
In the case of illiterate persons, consent forms and parental permission, as appropriate, shall be read to 
potential participants and obtained verbally.  A digital fingerprint, which is a legal form of documentation of 
consent in Brazil, will be collected from each patient in the consent and parental permission, which will also 
be signed by two individuals not directly involved in the study as witnesses.  All study participants will 
receive copies of the consent / assent form.  
 
If the patient or his/her guardian refuses to grant authorization for his / her participation through the signing 
of the TCLE or oral assent in the case of TALE, this will not entail any detriment to patient care. All 
participants or their guardians may also withdraw their consent at any time.  This does not cause any harm to 
the patient or their follow-up by the routine health service.  In case of changes in the TCLE or TALE after 
the approval of the original protocol by the committees of ethics of law, these should be submitted to afore 
mentioned committees and only from then on we can be used with new participants.   
 
A specific consent (Appendix C) will be required for patients over the age of 18 and their caregivers in cases 
of patients aged 5 to 17, inclusive, years for the storage of remaining samples after the study for use in 
malaria studies.   
 
Patients will receive contact information cards, including phone numbers for after-hours phone calls from the 
study team.  Consents must be filed minimum for 5 years, along with all other documents related to the 


18 
 
 
clinical study. The study coordination will define where these documents will be stored after the study is 
completed.   
 
Pregnancy testing  
In accordance to what is considered childbearing age in Brazil, all women 10 to 49, inclusive, years old 
being considered for the study will undergo a plasma or urine pregnancy test. Female participants who 
become pregnant during the study will be withdrawn if the pregnancy occurs while using chloroquine or 
primaquine. 
 
Enrollment procedures  
The nurse in the study team will evaluate the inclusion and exclusion criteria and explain the details of the 
study.  When an eligible patient agrees to participate in the study, he or she will be required to sign the 
Informed Consent Form (TCLE) and give oral assent, if applicable. 
 
In order to expedite the patient registration procedure, one of the microscopists trained for the study will 
review the blade stained by the health service and estimate the parasitemia on this slide. At this moment the 
patient is provisionally decided to include or not a patient while waiting for the coloration and reading of the 
blade taken by the study team.  
 
Study steps are the following:  
• Following the randomization table (Annex G), allocate each patient to one of the study groups using a 
pre populated randomization table obtained with SAS (SAS Institute, NC) or statistical software.  
Therefore, patient allocation will be determined in advance to the patient encounter itself. 
• A Case Report Form, consisting of demographic and clinical information (Appendix E). 
• Patient’s body weight and axillary temperature will be measured.  Results will be recorded on the 
Case Report Form.   
• On Day 0 (day of admission), all blood samples will be collected by one single venous drawing of 
approximately 7 ml in a dry collection tub.  The nurse, nurse assistant, or the laboratory technician 
will use the drawing to perform two sets of thick and thin smears to confirm malaria diagnosis and 
estimate parasitemia, he or she will put one drop of blood in each of the four circles of the 
Whatman® filter paper card, transfer 5.0 ml to a tube with EDTA for G6PD activity determination, 
and also hemoglobin level determination.  


19 
 
 
• Women aged 10 to 49, inclusive, years old, will also receive a pregnancy test, using either urine or a 
0.5 mL aliquot of the venous blood.   
• We will rely on the microscopist hired for this study to provide the first reading, allowing for patient 
enrollment and treatment initiation.  This professional will undergo a refresher training and 
competency evaluation by laboratorians from Instituto Evandro Chagas before study initiation.  
Within 24 hours after the first reading, a second microscopist also trained for this study will read 
slides, blinded to the first reading results (see below).   
• Four drops of blood will be collected on a filter paper, FTA classic cards by Whatman®.  This 
sample will be used for differentiation of reinfection vs. recrudescence and relapse during the follow-
up period (on or after Day 4).  This collection will be repeated in case of parasite reappearance on or 
after Day 4.   
• Five mL of blood will be collected in an EDTA tube on Day 0 to allow for G6PD activity 
determination.   
• One drop of blood will be used to determine the hemoglobin level on Days 0, 14, and 28.  Blood for 
hemoglobin on Days 14 and 28 will be obtained by fingerprick.   
• 2 mL of blood will be collected in an EDTA tube on Day 7 to allow for chloroquine level 
determination.  This collection will be repeated in case of parasite reappearance from Day 7 through 
Day 28.   
 
 


20 
 
 
Schedule of study procedures 
The following chart outlines the procedures and treatment for study subjects:  
 
Tasks  
Day 0 
(Enrollment) 
Day 1 
Day 2 
Day 3 
Day 7 
Day 14 Day 21 
Day 28 
to Day 
168 
(monthl
y, 6 
times)  
Any other 
day (after 
Day 3, if 
fever) 
Day of any 
recurrent 
parasitemia 
(on or after 
Day 4)  
Blood smear 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
Axillary 
temperature 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Focused history and 
physical exam 
X 
 
 
 
 
 
 
 
 
 
Review of 
symptoms and 
physical exam  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Blood for PCR in 
filter paper  
X 
 
 
 
 
 
 
 
 
X 
 


21 
 
 
Blood for G6PD 
(EDTA-coated 
tube) 
X 
 
 
 
 
 
 
 
 
 
Blood for CQ levels 
(EDTA-coated 
tube) 
 
 
 
 
X 
 
 
 
 
X1  
Hemoglobin level  
X 
 
 
 
 
X 
 
X, on 
Day 28 
only, not 
monthly 
afterwards 
 
 
Check G6PD result 
 
X 
X 
X 
X 
 
 
 
 
 
Treatment 
CQ2 dose  
X 
X 
X 
 
 
 
 
 
 
 
Primaquine3dose  
 
 
 
 
 
 
 
 
 
 
 
1. Blood for chloroquine level will only be taken during the first 28 days of follow up.   
2. See chloroquine doses on Tables 2 and 3.  
3. Primaquine should be initiated as soon as result of G6PD activity is available.  Primaquine course should be of at least seven or 14 
consecutive days, depending on the study group of the patient with doses adjusted for body weight as recommended (Table 4a and 4b).   
 
 
 


22 
 
 
Blood smear  
A Giemsa-stained thick blood film will be examined at 1,000x to identify parasite species and determine the 
parasite density.  Laboratory refresher training to be provided by colleagues from Instituto Evandro Chagas 
will cover these procedures.  Thick smears should be stained with diluted Giemsa stain (1:50, vol/vol) (or 
another) for 20 minutes.  Thin smears should be stained with diluted Giemsa stain (1:50, vol/vol) (or another) 
for 30 minutes.  Parasite density will be calculated by counting the number of asexual parasites using a hand 
tally counter against 200 white blood cells (WBCs) in the thick and thin smear, based on a WBC count of 
6,000 WBC/µl.  The parasite density per microliter will be calculated using the following formula:   
 
 
 
Parasite density/µl =   number of parasites counted x 6,000  
 
 
 
 
 
        number of WBC counted 
 
If the parasite count is <100 parasites/200 WBC, counting will be continued until 500 WBCs have been 
counted.  If no asexual parasites are found after counting 500 WBCs, the count will continue until 1,000 
WBCs are counted.  In other words, a total of 1,000 WBCs will be examined before a blood smear is 
considered negative.  Gametocytes will also be counted and number of gametocytes per microliter will be 
estimated on the same manner.   
 
All blood smears will be examined by two independent microscopists.  The first microscopist will be based 
at the clinic at the Hospital Regional do Jurua and the second at the malaria office at the Santa Casa de 
Cruzeiro do Sul.  This way the two initial readings will be done by professionals in Cruzeiro do Sul.  Blood 
smears with differences in species diagnosis or asexual parasite density of >50% between the two 
microscopists will be re-examined by a third, independent microscopist at Instituto Evandro Chagas or at the 
reference laboratory in Cruzeiro do Sul.  Asexual parasite density will be calculated by averaging the counts 
of the two concordant microscopists using geometric mean.   
 
Asexual parasite densities will be calculated by averaging the results of the two concordant microscopists 
using geometric mean.  Gametocytemia will be the arithmetic means of the same two readings.  The use of 
geometric and arithmetic means is decided based on the expected distribution of these values in previous 
similar studies.   
 
Antimalarial therapy  
All treatments will be provided free of charge to patients.  CQ (150 mg base) and primaquine (15 mg base 
and 5 mg of base) tablets will be obtained from reputable sources to guarantee quality.  We will use the 


23 
 
 
medication procured by the Brazilian Ministry of Health, which undergo regular quality control testing.  All 
doses of CQ and primaquine will be administered under supervision of a study team member for Groups 2 
and 3.  Only CQ doses will be overserved for Group 1.  Primaquine treatment will only be started for patients 
with documented normal activity of G6PD and will be given for seven or 14 consecutive days.  Patients with 
abnormal G6PD activity level will not undergo primaquine treatment, will be excluded from the study and 
referred for follow up at health facility.  These patients will need to be replaced to reach sample size.   
 
Patients will be observed for 30 minutes after treatment for adverse reactions or vomiting.  Any subject who 
vomits during this period will be retreated with the same dose of CQ or primaquine and observed for an 
additional 30 minutes.  If a subject vomits a second time, he/she will be referred for alternative treatment 
respecting referral policies in Cruzeiro do Sul.  Patient will be withdrawn from the study.   
 
Following national recommendations of Brazil, dosing of both CQ and primaquine will be adjusted by 
weight according to Tables 2 (a and b) and 3 (a and b) for the treatment of 7 or 14 days.   
 
 


24 
 
 
Table 2a. Dosing of CQ and primaquine for P vivax malaria treatment (Groups for 7 days) for patients ≤24 
Kg.   
 
Weight 
(kg)  
Number of pills per day  
Day 0 
Day 1 
Day 2  
Additional 4 
days  
CQ 
Primaquine 
(5 mg 
tablet)* 
CQ 
Primaquine 
(5 mg 
tablet)* 
CQ 
Primaquine 
(5 mg 
tablet)*  
Primaquine 
(5 mg 
tablet)*  
5–9 Kg 
1/2 
1 
1/4 
1  
1/4 
1  
1/2  
10–14Kg  
1 
2 
1/2 
1  
1/2 
1  
1  
15–24 Kg 
1 
2 
1 
2  
1 
2  
2  
* Attention: Primaquine not to be initiated until a normal value of G6PD activity is documented for the 
patient.   
 
Table 2b. Dosing of CQ and primaquine for P vivax malaria treatment (Groups for 14 days) for patients ≤24 
Kg.  
 
Weight 
(kg)  
Peso 
(kg)  
Número de comprimidos por dia  
Day 0 
Day 1 
Day 2 
Additional 4 
days 
7 additional 
days 
CQ Primaquine (5 
mg tablet)* 
CQ 
Primaquine (5 
mg tablet)* 
CQ Primaquine (5 
mg tablet)* 
Primaquine (5 
mg tablet)* 
Primaquine (5 
mg tablet)* 
5–9 Kg 
5 a 9 
kg 
1/2 
1/4 
1/4 
1/4 
1/4 
1/4 
1/4   
1  
10–
14Kg  
10 a 
14 
kg  
1 
1 
1/2 
1  
1/2 
1  
1  
1 and 1/2 
15–24 
Kg 
15 a 
24 
kg 
1 
2 
1 
2  
1 
2  
2  
2  
* Attention: Primaquine not to be initiated until a normal value of G6PD activity is documented for the 
patient.   


25 
 
 
Table 3a. Dosing of CQ and primaquine for P vivax malaria treatment for patients >25 kg (Groups for 7 
days).   
 
Weight 
(kg)  
Number of pills per day  
Day 0 
Day 1 
Day 2  
Additional 4 
days  
CQ 
Primaquine 
(15 mg 
tablet)* 
CQ 
Primaquine 
(15 mg 
tablet)* 
CQ 
Primaquine 
(15 mg 
tablet)*  
Primaquine 
(15 mg 
tablet)*  
25–34 Kg 
2 
1 
2 
1  
2 
1  
1 
35–49 Kg  
3 
2 
2 
2  
2 
2  
1 
≥50 Kg** 
4 
2** 
3 
2**  
3 
2**  
2** 
* Attention: Primaquine not to be initiated until a normal value of G6PD activity is documented for the patient.   
** Patients ≥70 Kgs will have to have the primaquine dose corrected by weight as shown in Tables 4a and 4b.   
 
 
Table 3b. Dosing of CQ and primaquine for P vivax malaria treatment for patients >25 kg (Groups for 14 
days).   
 
Weight 
(kg)  
Peso 
(kg)  
Número de comprimidos por dia  
 
Day 0 
Day 1 
Day 2  
11 additional days  
 
CQ 
Primaquine 
(15 mg 
tablet)* 
CQ 
CQ 
Primaquine 
(15 mg 
tablet)* 
CQ 
Primaquine (15 mg 
tablet)*  
25–34 
Kg 
25 a 
34 
kg 
2 
1 
2 
1  
1 
1  
1 
35–49 
Kg  
35 a 
49 
kg  
3 
1 1/2 
2 
1 1/2 
1 1/2 
1 1/2 
1 1/2 
≥50 
Kg** 
≥ 50 
kg** 
4. 
2** 
3 
2** 
2** 
2** 
2** 
* Attention: Primaquine not to be initiated until a normal value of G6PD activity is documented for the patient.   
** Patients ≥70 Kgs will have to have the primaquine dose corrected by weight as shown in Tables 4a and 4b.   
 
 


26 
 
 
In case of patients 70–120 Kgs, primaquine should be taken as a daily dose of 30 mg (2 adult pills) for a 
number of days according to patient weight (Tables 4a and 4b).   
 
Table 4a. Dosing of primaquine for P vivax malaria treatment for patients >70 kg (Groups 1 and 2).   
Weight 
Number of treatment days 
with primaquine (two 15 mg 
tablets per day)* 
Total dose (mg)**  
70–79 Kg 
8 
240 
80–89 Kg  
9 
272 
90–99 Kg 
10 
304 
100–109 Kg 
11 
336 
110–119 Kg  
12 
368 
* Attention: Primaquine not to be initiated until a normal value of G6PD activity is documented for the patient.   
** Total dose estimated.  
 
Table 4b. Dosing of primaquine for P vivax malaria treatment for patients >70 kg for groups taking 14 days 
of primaquine (Group 3).   
Weight 
Number of treatment days 
with primaquine (two 15 mg 
tablets per day)* 
Total dose (mg)**  
70–79 Kg 
17 
510 
80–89 Kg  
18 
540 
90–99 Kg 
21 
630 
100–109 Kg 
23 
690 
110–119 Kg  
26 
780 
* Attention: Primaquine not to be initiated until a normal value of G6PD activity is documented for the patient.   
** Total dose estimated.  
 


27 
 
 
Concomitant treatment  
Using standard healthcare practices in Brazil, study team members or clinic personnel will administer 
supportive treatment to subjects as necessary.  This include paracetamol, which will be given for axillary 
temperatures >38.0o C and parents/guardians will be instructed in the use of tepid sponging for children.  
Other conditions that may require additional treatment or evaluation will be referred to the reference center 
for specific follow up.   
 
Follow-up procedures  
Subjects will be asked to return to each one of the study sites on Days 1, 2, 3, 7, 14, 21, 28, and every four 
weeks until Day 168 (24 weeks mark).  On those visits a clinical assessment and blood collection via finger 
prick (except for Day 7, when venous puncture will be made) will take place.  We will not collect blood on 
Day 1.  In case patients cannot or do not wish to return to the health facility, arrangements will be made for 
patients to be visited at home by a study team member: the nurse during the period he/she has to take CQ, or 
the nurse assistant afterwards.  All CQ doses will be given as directly observed therapy.  Doses of 
primaquine will be observed only in patients in Groups 2 and 3. Tolerance of +/- 1 day will be allowed for 
visits on Day 14 or after.  
 
At all times, patients and any member of the study staff can count on the physician part of this study to 
evaluate patients and manage medical situations that might arise.  If unexpected situations arise, patients will 
be referred for treatment at routine services in Cruzeiro do Sul, including emergency services and 
hospitalizations if needed.  A schedule with dates of follow-up visits and contact information of study staff 
will be provided to participants.   
 
Since only ambulatory patients with uncomplicated malaria and a drug with well-known safety profile is 
being assessed as part of this protocol, there is no need for daily follow-up after treatment is finished.  
Subjects and parents/ guardians (in the case of participants less than 18 years old) will be encouraged to 
reach study team for further assessment and/or treatment at any point during follow-up at which the subject 
is perceived to be ill.  Telephone numbers and address of key study personnel will be provided to all 
participants at the time of enrollment.  Compensation for transport to and from the clinic can also be 
provided, for those patients that incur on transportation costs to come for the visits, or we can arrange a study 
staff to visit you at your home or pick up you up for the visit.   
 


28 
 
 
When the research subject is female and pregnancy occurs before the end of the treatment with chloroquine 
and primaquine, there will be interruption of their participation in the research and it will be referred to the 
assistance of the municipality regarding the care of pregnant women with malaria.  If a patient becomes 
pregnant after treatment with chloroquine and primaquine, the participant will remain in the study.   
 
During the consent procedure, we will ask patients and their guardians to keep samples for future malaria 
studies (Annexes C1, C2, C3).  The sample collected represents the minimum necessary for the purposes 
described in this study and the remaining aliquots will be minimal.  We will not increase volumes of samples 
in order to have leftovers for stocking.  In the case of non-concurrence with leftover storage, any leftover 
filter paper will be destroyed 2 years after the study and even during this period will only be used for assays 
related to this study and already described in this protocol, such as in need of repeating assays to confirm 
results.    
 
Chloroquine blood levels  
To aid in the interpretation of treatment failures during the first 28 days of follow-up (reappearance of 
parasitemia between Days 4 and 28), blood levels of CQ and its major metabolite desethylchloroquine 
(DCQ) will be measured on Day 7 and at the time of any reappearance of parasitemia from Day 7 to Day 28.  
A blood level of CQ plus DCQ ≥100 mg/ml (equivalent to ≥15ng/ml in plasma), in the presence of P. vivax 
parasites in the blood is highly suggestive of CQ resistance.   
 
To permit this assessment, 2 ml of blood will be taken by venipuncture from all patients on Day 7 and again 
at the time of any recurrent parasitemia on or before Day 28, in an heparin tube and stored in a cold chamber 
at 4° C.  Chloroquine and DCQ levels will be measured by high-performance liquid chromatography (HPLC) 
by reference laboratories at laboratories in Brazil.(WHO 2009, Miranda, Silva et al. 2015)  
 
Molecular analysis 
Microsatellite genotyping   
We plan to use the microsatellite markers described by Imwong et al. for P. vivax in this study.(Imwong, 
Sudimack et al. 2006)  In brief, in case of parasitemia appearing on or after Day 4, blood collected on the day 
of the parasite reappearance will be processed in pair with sample collected on Day 0.  Polymerase chain 
reaction (PCR) aiming to amplify the microsatellites previously described will be conducted.  Fluorescent-
labeled PCR products will be analyzed and when the size of an allele was at least different for more than two 
base pairs from other alleles, it will be considered a different allele.  This work will be conducted by 


29 
 
 
collaborators at Instituto Evandro Chagas in Brazil with support from CDC/Atlanta, but we can extract the 
DNA from the parasite contained in the collected material and send this aliquot to the CDC laboratories in 
Atlanta if necessary for processing and quality control.   
 
CYP2D6 genotyping and metabolic activity phenotyping  
We also plan to analyze CYP2D6 gene polymorphisms and to correlate those to metabolic activity 
phenotypes.(Gaedigk, Dinh et al. 2018, Caudle, Sangkuhl et al. 2020) Seven single nucleotide 
polymorphisms; C-1584G (rs1080985), C100T (rs1065852), C1023T (rs28371706), G1846A (rs3892097), 
G31A (rs769258), G3183A (rs59421388), and G4180C (rs1135840); and one deletion, 2615_2617delAAG 
(rs5030656), will be genotyped using all day 0 samples by TaqManTM SNP Genotyping Assays (Thermo 
Fisher Scientific, Waltham, Massachusetts, USA ). We will perform amplifications, fluorescence detection, 
and analysis using StepOnePlusTM Real-Time PCR System (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA). Then we will determine enzyme metabolic activity scores (ASs) for each haplotype: 
poor metabolizer (AS= 0), intermediate metabolizer (AS= 0.25–1.00), normal metabolizer (AS= 1.25–2.25), 
and ultrarapid metabolizer (AS >2.25)(Gaedigk, Simon et al. 2008, Friedrich, Genro et al. 2014, Caudle, 
Sangkuhl et al. 2020). This work will be conducted by collaborators at Instituto Evandro Chagas with 
support from Federal University of Pará State in Brazil. 
 
 
Outcome measures  
The efficacy and lack of efficacy of the drug being evaluated will be based on an assessment of the 
parasitologic and clinical outcomes recommended by WHO (WHO 2009).  These definitions are valid only 
for the initial 28 days of follow-up.  These are:   
 
• Early Treatment Failure (ETF), if patient develops one of the following conditions during the first 
three days of follow-up:  
o Development of danger signs or severe malaria on Days 1, 2, or 3, in the presence of asexual 
parasitemia;  
o Asexual parasitemia on Day 2 >Day 0 count in disregard to presence of fever;  
o Asexual parasitemia on Day 3 in the presence of axillary temperature ≥37.5°C;  
o Asexual parasitemia on Day 3 >25% of Day 0 count.  
• Late Treatment Failure (LTF), if patient develops one of the following conditions during the follow-
up period from Day 4 to 28:  


30 
 
 
o Late clinical failure (LCF)   
• 
Development of danger signs or severe malaria in the presence of asexual parasitemia 
on any day from Day 4 to Day 28, without previously meeting any of the criteria of 
ETF, or  
• 
Axillary temperature ≥37.5°C (or history of fever), in the presence of asexual 
parasitemia on any day from Day 4 to 28, without previously meeting any of the 
criteria of ETF.   
o Late parasitological failure (LPF)   
• 
Presence of asexual parasitemia on any day between Days 7 and 28 and axillary 
temperature <37.5ºC without previously meeting any of the criteria of ETF or late 
clinical failure.  
• Adequate Clinical and Parasitological Response (ACPR), if patient shows the following conditions 
during the 28-day follow-up period:  
o Absence of asexual parasitemia between Days 14 and 28 without previously meeting any of 
the criteria of ETF or LTF. 
 
The resurgence of malaria symptoms with proven parasitemia between Day 28 and Day 168 will be 
classified as Failure in Extended Follow-up.  
 
Besides that, we will also consider a simplified outcome algorithm recommended by WHO as follows: Day 
28 treatment failure defined as (1) clinical deterioration due to P. vivax illness requiring hospitalization in the 
presence of parasitemia, (2) presence of parasitemia and fever (axillary temperature ≥37.5 °C) on any day 
between days 3 and 28; or (3) presence of parasitemia on any day between days 7 and 28, irrespective of 
clinical condition. The resurgence of parasitemia between days 28 and 168, with or without fever, will be 
classified as extended follow-up failure. A day 28 adequate clinical and parasitological response (ACPR) 
will include participants who will not meet criteria for day 28 treatment failure; we also ascertained day 168 
recurrence-free proportion as patients who will not meet any failure criteria during the entire follow-up. 
Participants with treatment failure will be withdrawn and referred for rescue treatment. 
 
PCR results will be used to elucidate whether these cases are due to homologous isolates (same genotypic 
profile between Day 0 isolate and day of reinfection) or heterologous (different genotypic profiles between 
Day 0 isolate and day of reinfection).   
 


31 
 
 
We will perform analysis per protocol and intention to treat, and plan to report both on study reports.  In all 
cases of therapeutic failure, patients will be withdrawn from the study and referred to the routine treatment 
service according to Brazilian Health Ministry regulations.   
 
Loss to follow-up  
Loss to follow-up occurs when, despite all reasonable efforts, an enrolled patient cannot be found.  Include 
failure to find a patient in the community after he or she misses a scheduled follow-up visit.  Except for the 
period patient is taking CQ, it is acceptable for patients to be seen on the day before or day after the schedule 
visit before he/she is considered loss of follow-up.  In addition, any patient who leaves the study area is also 
considered loss of follow-up.  Patients who are lost to follow-up should be distinguished from those who 
voluntarily leave the study.  If a patient is lost to follow up during the period she/he is receiving medications, 
all efforts will be made by the study team to locate patient and guarantee he/she takes all doses.   
 
Withdrawal from study  
A study patient (or a study patient’s parent or guardian) who decides not to participate any further in the 
study is referred to as a voluntary withdrawal.  An example of a cause for involuntary withdrawal would 
development of a concomitant illness that would interfere with the clear interpretation of study outcomes.   
 
Participation interruption  
In some instances, a participant may be removed  from the study because of an event that does not allow for 
continued accurate interpretation of response to treatment.  Examples include missed treatment dose, 
detection of a mixed infection during follow-up, or a credible report of additional antimalarial drug use 
outside the study protocol (such as self-medication).   
 
Subjects meeting any of the following criteria will be withdrawn from follow-up (include reasons for 
voluntary and involuntary withdrawal):  
1. Withdrawal of consent  
2. Failure to complete the CQ treatment as prescribed.  We will tolerate one day for the primaquine 
doses  
3. Low levels of G6PD activity, these patients will require another patient to be admitted as a 
replacement   
4. Persistent vomiting during the treatment with either CQ or primaquine  
5. Erroneous inclusion of a patient outside of the inclusion/exclusion criteria 


32 
 
 
6. Severe side-effects (see below)   
7. Occurrence during the follow-up of concomitant disease that would interfere with a clear 
classification of the treatment outcome  
8. Need for or receipt of blood transfusion  
9. Detection of another malaria species infection during the follow-up.  These patients will be referred 
for appropriate treatment.    
10. Antimalarial (or antibiotics with antimalarial activity) treatment administered by a third party or self-
medication with antimalarial (or antibiotics with antimalarial activity) (doxycycline, clindamycin, 
etc)  
11. Failure to attend scheduled visits within the +/- 1 day of tolerance on or after Day 14 Severe malaria 
occurring after enrollment  
12. Misclassification of a patient due to a laboratory error (parasitemia) leading to the administration of 
the rescue treatment  
 
The cause of withdrawal from the study or loss to follow-up will be recorded in the Case Report Form.  In 
case of items from 1 to 6 listed above, patients will be excluded from all analysis in the other instances, we 
will censor patient data until the day of the event.   
 
Adverse events  
Occurrence of side-effects associated with the study drugs or procedures will be closely monitored and 
recorded on appropriate form (Annex F).  Patients with side-effects necessitating medical treatment or 
hospitalization will be referred for appropriate treatment.  Study participation may be discontinued if it is 
established that study procedures cannot be safely continued, such as study drug allergic events during 
treatment or G6PD deficiency, for that study participant.  Of note, patients with skin rash or any severe 
allergic reaction will be withdrawn from the study, while patients experiencing only itching will not be 
withdrawn from the study.  In addition, adverse events that are unexpected, likely related to the research 
study, and that place the participants at greater risk of harm will be reported to the local and CDC IRBs in 
accordance with required reporting schedules after their occurrence, i. e., in no later than 2 working days of 
CDC awareness.   
 


33 
 
 
Alternative treatment 
Patients with intolerance to the therapy, therapeutic failure, or reinfection with P. vivax infection will be 
referred to reference health facility with alternative treatment.  Alternative treatment will be decided by 
attending physician.   
 
Limitations  
The findings of this study are limited to the catchment area of the study health facilities in Northwest Acre 
state.  We acknowledge that results may not be representative of the whole country.  In addition, only 
consenting participants will be included, which may introduce selection bias in the study.  These points will 
be taken into consideration for interpretation of results.   
 
Ethical considerations 
Consent procedure:  Informed consent or permission will be asked from adult participants and child’s 
parents or guardian (in case of <18 years old) for those who meet the study inclusion criteria.  The age of 
majority in Brazil is 18 years (Appendices A1 and A2).  For participants 7 to 17, inclusive, years old, we will 
also ask for his/her verbal assent (Appendices B1 and B2); assent will not be asked for children 5 through 6 
years old.  In case of illiterate participants, we will read the consent/ assent and two witnesses not associated 
with the study will be asked to sign the forms; and the participant’s or guardian’s fingerprint, which is a legal 
form of documentation of consent in Brazil, will be added to the respective forms.  Signed consent forms 
will be kept separate from case report forms.  The study details, participant benefits, and possible risks will 
be explained in Portuguese, the national language in Brazil.  All patient information will be kept confidential.  
Unique numerical identifiers, and not personal identifiers, will be used for data entry and analysis.   
 
Any patients who decide not to enter the protocol will be evaluated as usual by the healthcare facility 
personnel as customary with no prejudice to the patient or his/her family.  In case of confirmed malaria, the 
patient will be treated in accordance to the guidelines from the National Malaria program in Brazil.   
 
Procedure and risks:  There is an inherent minimal risk associated with the finger sticks and venipunctures, 
which are to be performed as part of this study.  The patient may experience a brief moment of discomfort 
and/or fear during the finger stick or venipuncture and the puncture area may get infected or bruised.  We 
estimate that a total of 10 finger pricks will be needed for each study participant, in addition two blood 
drawing, one of 7 ml on Day 0 and the other of 2 ml on Day 7, will be taken from the patients.  It may be 
required to collect additional blood in case of suspicion of recurrent infection. Blood collections were 


34 
 
 
reduced to the minimal necessary and we will make sure trained phlebotomists and/or laboratory technicians 
perform those to minimize risks and discomfort.  In addition, to reduce risks, we tried to combine blood 
collections to be done on the same day in a way to collect blood with just one of the procedures.  Separate 
consent/assent (Annexes C1, C2, C3) will be required for storage of remaining material from the samples.  If 
no authorization is given, all material from that patient will be destroyed upon completion of the analysis of 
the study, estimated at two years after its closure. This material will only be used for malaria assessments.   
 
A minority of patients may experience drug side effects. The side effects most commonly associated with 
CQ are nausea, vomiting, rash, headache, dizziness, urticaria and abdominal pain.  On rare occasions, higher 
doses of CQ have been associated with aplastic anemia. Commonly reported side effects of primaquine 
include hemolysis in patients with G6PD deficiency and gastrointestinal symptoms. We note that the 14-day 
primaquine group is receiving a higher dose of the drug than recommended by the Brazilian malaria co-
ordination, but it is within the WHO recommendations.(WHO 2015)  
 
Benefits:  The participants in this study have some direct and indirect benefits.  Patients will receive 
supervised treatment for malaria and will be closely monitored to check the efficacy of it.  In addition, 
participants will be examined and referred for treatment of other concurrent illnesses.  At each visit, the 
patient or his/her guardian will be informed of his/her physical status and the medical procedures that will 
take place.  The patient’s health condition will be closely monitored during the duration of the study.  
Patients will be encouraged to return for the follow-up visit and in case they do not return, a member of the 
investigation team will perform a home visit.  Indirectly, this study will also allow a better understanding of 
the efficacy of P. vivax malaria treatment in the Amazon region of Brazil.  This will ensure policies in Brazil 
are in place to reduce the morbidity and mortality of malaria.   
 
Patient selection:  Malaria affects both children and adults in Brazil.  The methods to monitor malaria and 
evaluate national policies published by the WHO  recommends enrollment of patients that are representative 
of the population (WHO 2009).  For this reason, adults and children ≥5 years old will be enrolled in the 
present study.   
 
Confidentiality:  All study forms and materials will be kept in locked cabinets and locked rooms.  Patients’ 
identifiers will be available to Cruzeiro do Sul study personnel only to allow for patient follow-up.  
Electronic databases will be password protected and will not contain personal identifiers.  In spite of all of 


35 
 
 
these precautions to maintain confidentiality of the data, it is possible that the confidentiality could be 
compromised.  We will make our best efforts to avoid dissemination of any personal information. 
 
Experimental products or procedures:  No new therapies, products, or procedures will be used in this 
study.  The use of CQ and primaquine is a practice in Brazil and routinely recommended for treatment of P. 
vivax infections.  We will, however, evaluate a higher dose of primaquine that than the one recommended in 
Brazil, but this dose is already recommended by WHO.(WHO 2015, Negreiros, Farias et al. 2016)  
 
Data management  
All forms and files will be kept at a safe place in Cruzeiro do Sul, Acre state, Brazil.  File cabinets and rooms 
where data are stored will be protected by keys and locks and only study investigators will have access to 
them.  Personal identifiers are collected mainly for follow-up reasons, i.e. to allow for patient to be located in 
case of no show to follow up appointments.  This information will not be entered on electronic databases, nor 
will it be used during the analysis phase.   
 
Case report forms and other study information will be entered in an electronic database in Microsoft Access 
or equivalent, which will be under responsibility and ownership of the field investigators in Cruzeiro do Sul.  
No personal identifier will be entered in the electronic databases.  A copy of the database, which by design 
will not contain any personal identifier, will be shared with co-investigators at CDC and IEC for assistance 
with analysis.   Statistical programs, such as Epi-Info (Centers for Disease Control and Prevention, Atlanta, 
GA) and SAS (SAS Institute, NC), will be used for data management and analysis.   
 
Statistical analysis 
Data will be analyzed using two methods: first, by survival analysis where all enrolled patients (including 
those who were withdrawn from the study or who were lost to follow-up) will be included; second, by the 
traditional method where patients excluded from the study or lost-to-follow-up during the course of the 
project are not included.   
 
The number and proportion of subjects who have treatment failures and ACPRs, as defined above, by Day 28 
will be calculated.  This is the main and primary outcome measure for treatment efficacy.  Potential risk 
factors (e.g., age, initial parasite density, etc.) will be assessed for an association with the probability of a 
therapeutic failure and the time to therapeutic failure.  Percentages of P vivax infections from Day 29 to Day 
168 will be evaluated.   


36 
 
 
 
Dissemination of results  
All results will be shared with the Ministry of Health of Brazil and its partners.  The Ministry of Health will 
make the final determination as to how the results should be presented to the regional and local health 
officers.  Results will also be submitted to peer-reviewed scientific journals and presented at national and 
international meetings.   
 
At the time participants complete the study (Day 168), or earlier if they have had a therapeutic failure, they 
will be informed verbally by study staff of the outcome/results of their treatment.  At enrollment and at the 
end the study, the investigation team will inform patients about points of contact at the healthcare facility and 
Ministry of Health levels to obtain the study findings.  The Ministry of Health will determine such points of 
contact.   
 
Budget  
The funds for this study will come from CDC as part of AMI/RAVREDA and will be used to hire project 
coordinator, nurses, nurse assistants, and microscopists.  The budget also accounts for laboratory testing to 
take place in Cruzeiro do Sul.  Other study-related costs, such as study drugs, sample collection supplies, and 
office supplies, are not included because those refer mainly to materials and consumables that will be 
purchased directly by partner institutions and shipped to study site.   
 


37 
 
 
Table 5.  Budget for field costs  
 
Expense 
Cost (R$) 
Number of 
months 
Total Cost 
(R$) 
Total Cost 
(US$) 
Justification 
Principal 
investigator 
1,000.00 per 
month 
12 
12,000.00 
4,000.00 
Study 
coordination 
Nurse 
3,200.00 per 
month 
12 
38,400.00 
12,800.00 
This professional 
will have direct 
oversight of 
teams 
Nurse 
2,600.00 per 
month 
12 
31,200.00 
10,400.00 
This professional 
will have direct 
oversight of 
teams 
Nurse assistant 
1,000.00 per 
month 
12 
12,000.00 
4,000.00 
Follow up visits  
Nurse assistant 
1,000.00 per 
month 
12 
12,000.00 
4,000.00 
Follow up visits 
during enrolment 
period (8 months 
only)  
Microscopist 
1,000.00 
12 
12,000.00 
4,000.00 
 
Microscopist 
1,000.00 
12 
12,000.00 
4,000.00 
Part-time 
G6PD testing 
100.00 per 
sample 
250 
25,000.00 
8,333.33 
 
Laboratory 
supplies 
(needles, 
syringes, tubes, 
etc) 
12,000.00 
NA 
12,000.00 
4,000.00 
This will be 
provided at no 
cost to study 
team by partner 
organization. 
Total 
 
 
164,250.00 
56,393.67 
 
 


38 
 
 
References  
Alecrim, M. d. G., W. Alecrim and V. Macedo (1999). "Plasmodium vivax resistance to chloroquine (R2) 
and mefloquine (R3) in Brazilian Amazon region." Rev Soc Bras Med Trop 32(1): 67-68. 
Baird, J. K., H. Basri, B. Subianto, D. J. Fryauff, P. D. McElroy, B. Leksana, T. L. Richie, S. Masbar, F. S. 
Wignall and S. L. Hoffman (1995). "Treatment of chloroquine-resistant Plasmodium vivax with chloroquine 
and primaquine or halofantrine." J Infect Dis 171(6): 1678-1682. 
Baird, J. K. and S. L. Hoffman (2004). "Primaquine therapy for malaria." Clin Infect Dis 39(9): 1336-1345. 
Caudle, K. E., K. Sangkuhl, M. Whirl-Carrillo, J. J. Swen, C. E. Haidar, T. E. Klein, R. S. Gammal, M. V. 
Relling, S. A. Scott, D. L. Hertz, H. J. Guchelaar and A. Gaedigk (2020). "Standardizing CYP2D6 Genotype 
to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation 
Consortium and Dutch Pharmacogenetics Working Group." Clin Transl Sci 13(1): 116-124. 
Centers for Disease Control and Prevention, C. (2015). Malaria Treatment (United States). 
Collins, W. E. and G. M. Jeffery (1996). "Primaquine resistance in Plasmodium vivax." Am J Trop Med Hyg 
55(3): 243-249. 
Costa, K. (2009). Malaria e psicultura em Cruzeiro do Sul (Amazonia ocidental brasileira): analise de seria 
historica, 1998-2008. Masters, Universidade do Estado do Amazonas  
Durand, S., C. Cabezas, A. G. Lescano, M. Galvez, S. Gutierrez, N. Arrospide, C. Alvarez, M. L. Santolalla, 
D. J. Bacon and P. C. Graf (2014). "Efficacy of three different regimens of primaquine for the prevention of 
relapses of Plasmodium vivax malaria in the Amazon Basin of Peru." Am J Trop Med Hyg 91(1): 18-26. 
Friedrich, D. C., J. P. Genro, V. A. Sortica, G. Suarez-Kurtz, M. E. de Moraes, S. D. Pena, A. K. dos Santos, 
M. A. Romano-Silva and M. H. Hutz (2014). "Distribution of CYP2D6 alleles and phenotypes in the 
Brazilian population." PLoS One 9(10): e110691. 
Gaedigk, A., J. C. Dinh, H. Jeong, B. Prasad and J. S. Leeder (2018). "Ten Years' Experience with the 
CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for 
Precision Therapeutics." J Pers Med 8(2). 
Gaedigk, A., S. D. Simon, R. E. Pearce, L. D. Bradford, M. J. Kennedy and J. S. Leeder (2008). "The 
CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype." Clin 
Pharmacol Ther 83(2): 234-242. 
Hill, D. R., J. K. Baird, M. E. Parise, L. S. Lewis, E. T. Ryan and A. J. Magill (2006). "Primaquine: report 
from CDC expert meeting on malaria chemoprophylaxis I." Am J Trop Med Hyg 75(3): 402-415. 
Imwong, M., D. Sudimack, S. Pukrittayakamee, L. Osorio, J. M. Carlton, N. P. Day, N. J. White and T. J. 
Anderson (2006). "Microsatellite variation, repeat array length, and population history of Plasmodium 
vivax." Mol Biol Evol 23(5): 1016-1018. 
Miranda, T. A., P. H. Silva, G. A. Pianetti and I. C. Cesar (2015). "Simultaneous quantitation of chloroquine 
and primaquine by UPLC-DAD and comparison with a HPLC-DAD method." Malar J 14: 29. 


39 
 
 
Negreiros, S., S. Farias, G. M. Viana, S. A. Okoth, S. M. Chenet, T. M. de Souza, P. Marchesini, V. 
Udhayakumar, M. M. Povoa, A. C. Santelli and A. M. de Oliveira (2016). "Efficacy of Chloroquine and 
Primaquine for the Treatment of Uncomplicated Plasmodium vivax Malaria in Cruzeiro do Sul, Brazil." Am 
J Trop Med Hyg 95(5): 1061-1068. 
Oliveira-Ferreira, J., M. V. Lacerda, P. Brasil, J. L. Ladislau, P. L. Tauil and C. T. Daniel-Ribeiro (2010). 
"Malaria in Brazil: an overview." Malar J 9: 115. 
PAHO. (2003). "Generic Protocols and Flow Diagram for in vivo Antimalarial Drug-Efficacy Studies in the 
Americas."   Retrieved June, 2012 from http://www.paho.org/english/ad/dpc/cd/mal-antimalarials.htm. 
PAHO. (2012). "RAVREDA-AMI: Amazon Network for the Surveillance of Antimalarial Drug Resistance 
(RAVREDA) / Amazon Malaria Initiative (AMI)."   Retrieved June 28, 2012, from 
http://www.paho.org/english/ad/dpc/cd/ravreda-ami.htm. 
Phillips, E. J., J. S. Keystone and K. C. Kain (1996). "Failure of combined chloroquine and high-dose 
primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America." Clin Infect Dis 
23(5): 1171-1173. 
Rieckmann, K. H., D. R. Davis and D. C. Hutton (1989). "Plasmodium vivax resistance to chloroquine?" 
Lancet 2(8673): 1183-1184. 
Silveira, A. (2001). "Avaliacao da estrategia global de controle integrado da malaria no Brasil." Organizacao 
Pan-Americana de Saude. 
Soto, J., J. Toledo, P. Gutierrez, M. Luzz, N. Llinas, N. Cedeno, M. Dunne and J. Berman (2001). 
"Plasmodium vivax clinically resistant to chloroquine in Colombia." Am J Trop Med Hyg 65(2): 90-93. 
WHO (2008). Global Malaria Control and Elimination: Report of a Technical Review. 
WHO (2009). Methods for Surveillance of Antimalarial Drug Efficacy. 
WHO (2015). Guidelines for the treatment for malaria: 316. 
WHO. (2015). "Guidelines for the Treatment of Malaria ", from https://www.who.int/docs/default-
source/documents/publications/gmp/guidelines-for-the-treatment-of-malaria-eng.pdf?sfvrsn=a0138b77_2. 
 


40 
 
 
Appendix A1: Consent Form. Informed Consent Form for Patients Aged 18 years and older.  (Flesh-
Kincaid 7.6)  
Project: Efficacy of High Total Dose of Primaquine to Prevent Plasmodium vivax Malaria Relapses in 
Cruzeiro do Sul, Brazil  
 
 
Purpose  
The Brazilian Ministry of Health is working with the Municipal Health Secretariat, State Department of 
Health of Acre, the Evandro Chagas Institute and the Centers for Disease Control and Prevention (CDC) in 
the United States of America. They are working on an evaluation of the malaria treatment in Cruzeiro do Sul, 
Acre.  Malaria is a disease caused by a parasite that infects cells in your blood.   
 
The goal of this research is to see if the drugs used to treat malaria are working. We will evaluate treatment 
with chloroquine and primaquine for vivax malaria.  This is the kind of malaria most common in Brazil.  
 
This evaluation is being coordinated by Dr. Suiane Negreiros do Valle. She is a physician at the State 
Department of Health of Acre, and she works at the Hospital Regional do Jurua.   
 
We intend to include a total of 257 people aged 5 years and over in this assessment.  
 
If you agree, we intend to follow you during the malaria treatment and for six months after the malaria 
treatment. We will collect blood samples during this time. This is to know if you are free of malaria. If you 
choose not to take part, you will be treated in the same place with the same medications without any loss or 
penalty. 
 
Getting Started  
After the positive result for malaria vivax, we will place you in one of three groups in this study.  The 
decision to which group you will enter will be random, which means it is by chance like flipping a coin.  One 
group will receive the three-day treatment with chloroquine under supervision and will take primaquine 
treatment at home for seven days.  This is the recommended practice by the Ministry of Health.  Another 
group will receive chloroquine treatment for three days and primaquine for seven days under supervision.  
The third group will also receive complete treatment under supervision but primaquine will be given for a 


41 
 
 
total of 14 days under supervision.  In this last group, the total dose of primaquine is higher than the one 
currently recommended in Brazil, but it is within the recommendations by the World Health Organization.  
 
We will ask you some questions to know your general health and condition of your current illness. We will 
ask you some questions to know your age and for how long you have been sick.  You do not have to answer 
any questions you do not want to answer.  In addition, you can decide at any time that you no longer want to 
take part in this survey without penalty. Your care at the health clinic will not change in quality if you choose 
not to respond or do not want to take part in this study. We also want to examine you and collect blood 
samples to confirm that you have malaria. We will collect a small amount of blood (about 7 ml, a tea spoon 
and a half) of blood from the vein in your arm. This blood will be used to confirm the diagnosis of malaria.  
It will also confirm you have an active substance in your blood to be able to tolerate the treatment with 
primaquine.  We will do these tests right here in Cruzeiro do Sul.  After these initial tests, the blood will be 
stored for other laboratory tests to compare the response to the treatment in case you have another malaria 
episode during the follow-up.  These new tests will be conducted at the Evandro Chagas Institute in Belém 
do Pará.  A small part of the parasite material may be sent to the Centers for Disease Control and Prevention 
in the USA.   
 
After blood collection and confirmation of the diagnosis, we will immediately start treatment with 
chloroquine. The dose of medication and the number of days of treatment depend on your weight.  For the 
chloroquine dose, we follow the guidelines and recommendations of the Ministry of Health of Brazil.  This 
means this medication is the same one that you would be receiving even if you did not take part in this study.  
Chloroquine should be taken for a total of three days.  We will ask you to come to this place to receive 
treatment from our hands. This is true for all three study groups.  We can go to your home if you prefer.  
Chloroquine is well tolerated.  It can cause nausea and some pain in the belly within the first few hours after 
taking in some cases. There is also the risk of allergy to the medicines.  At each of these visits, three more 
visits after today, we need to collect four drops of blood from the tip of your finger and also give you 
chloroquine for two more days.  We will not need to collect blood from you tomorrow.   
 
When we get the results of your laboratory tests, we will start primaquine treatment. This drug is 
complementary to chloroquine treatment.  It is also routinely indicated by the Brazilian Ministry of Health.  
It is usually taken for a total of seven days. As part of this study, you may be asked to take it for 14 days.  
This , which is different than the recommendation in Brazil, but within the limits recommended by the World 
Health Organization. Depending on your weight, you may need to take primaquine for a few more days. You 


42 
 
 
will need to take the medicine either in front of the health professional or at home, depending on the study 
group.  Since it will not be necessary to collect blood all these days, you can decide if you prefer to come 
here.  We can also come to your house to give the drug.   
 
Treatment and evaluation will be free of charge. The interview, examination, and blood collection will take 
about 30 minutes on the first visit.  It will take about 15 minutes on the next visits.  We recommend you 
sleep under mosquito net with insecticide. This will protect you from malaria.   
 
Follow-Up  
After treatment of malaria, we would like to visit you on a weekly basis for the first 28 days after malaria 
diagnosis.  Afterwards, we would like to visit you once a month until six months are complete. It is 
important that you can take part in those visits.  Please let us know if you think that would not be possible.  
During those visits, we will check your health and collect two drops of blood from your finger.  This is to see 
whether the malaria has been treated.  If the malaria comes back, we will refer you for treatment.  The results 
of those tests are available the same day.  We will let you know the results.  On the seventh day of follow-up, 
we need to collect a blood sample of more or less 2 mL (less than a teaspoon) from the vein in your arm.  
This is to measure the levels of chloroquine.  In total, there will be 10 samples from the fingertips and two 
blood samples from the vein in your arm.  We will give you a card with the visit scheduling.   
 
For women, we will perform a urine or blood pregnancy test at the beginning of the study for women less 
than 50 years old.   If you are a woman of any age and become pregnant while taking the medication, we will 
need to stop your participation.  You will be referred for treatment of malaria by a reference service here in 
Cruzeiro do Sul.  If you become pregnant after you have finished the drugs, we will follow you as planned.   
 
If you have any health problems or have any questions, please contact Dr. Suiane at the Hospital do Jurua in 
Cruzeiro do Sul.  You can also contact the person who is seen you today here or at the Sala de Estudos em 
Malaria na Santa Casa.  A member of the team will be able to assess you even if it is not the day of your visit 
at the clinic.  The address of the hospital and sala de Estudos are:  
Hospital Regional do Juruá   
 
 
Santa Casa de Misericórdia  
Rua 25 de agosto, 5121  
 
 
 
Rua Lauro Muller, 473  
BairroAeroporto Velho 
 
 
 
Bairro Manoel Terças  
Sala ao lado da CERIMAGEM  
Phone:  
(XX) XXXX XXXX  
 
(XX) XXXX XXXX 


43 
 
 
 
 
Risks and Discomfort  
There is some discomfort and a small risk if you decide to take part in this study. You may have minimal 
pain when the blood is collected. Our team is well trained to avoid this.  In rare cases, there occurs light 
bleeding or bruising. If any injury occurs, we will take steps for you to receive the proper care.  We think it is 
very unlikely you will have any harm.   
 
Benefits  
There will be direct and indirect benefit for you upon taking part in this study. As part of this study, we will 
closely monitor you with respect to your disease. So, we will be able to offer you any additional treatment 
very quickly if you need it. Your participation will also assist the Brazilian malaria program to know if the 
malaria drugs are still working.   
 
Compensation  
You will not receive any compensation for participating in this study.  However, we can reimburse you for 
food and transportation costs to attend the clinic visits.  If you need to be hospitalized, this will be done at a 
facility of the public health service in Brazil free of charge for you. Under the care of the study physician.   
 
Confidentiality  
We will keep your information confidential to the full extent permitted by the law. Your name will be used 
only during the time you come for your appointment or we visit your house.  We will not share your name 
with people outside of the study group or outside Cruzeiro do Sul. None of the reports from this study will 
contain your name.  Patient’s forms will be kept in locked cabinets.  Your personal information will not be 
used for any purpose during this study.   
 
Contact Information  
If you have any questions or feel you have been harmed by being in the study, contact:  
 
• Dr. Suiane Negreiros do Valle, general coordinator of the project in Cruzeiro do Sul, phone (XX) 
XXXX XXXX.  
• Dr. Paola Marchesini, researcher, responsible for the follow-up of this study with the coordination of 
the Brazilian Malaria Program in Brasilia, phone (XX) XXXX XXXX.   


44 
 
 
 
You can contact Dr. Arnaldo (information below) if you have any questions.  She is available to answer 
questions about your rights as a participant. She is able to explain your rights as a patient in this study.  She 
is not directly involved in this study, but her role is to make sure your, rights are respected.   
 
Arnaldo Jorge Martins Filho 
Coordenador do Comitê de Ética em Pesquisa do Instituto Evandro Chagas - CEP/IEC 
Rodovia Br - 316, km 7 s/n 
67.030-000 Levilandia 
Ananindeua, Pará, Brasil 
Phone: (XX) XXXX XXXX 
Voluntary participation, refusal and withdrawal  
Several aspects of this study are very important. Remember that:  
• You are free to decide if you want to take part in this study or not. If you decide not to take part, 
you will receive the necessary free routine care and treatment, including for malaria. You will 
not incur any penalty or loss for not taking part. 
• You are free to withdraw from this study at any time. That fact will not affect your treatment or 
the care received.  You will still receive the routine free treatment for malaria.  
• In some situations, if you develop side effects to the treatment or you get malaria, we may need 
to withdraw you from the study.   
• There is no cost to you for taking part in this study.  
• You may let me know now if you have any questions with respect to the study.  You can also 
ask questions about your participation.   
 
Declaration of Consent  
Upon signing or providing a fingerprint indicating legal consent for the appropriate declaration, I agree that:  
• I have read this form or the form was read to me by someone else  
• I was able to ask questions about the study. My questions have been answered  
• I agree in a voluntary manner to participate in this study  
• I was informed that I have the right to withdraw from the study at any time. That will not affect the 
care given to me.   
 
 


45 
 
 
Study participant’s name: ________________________________ Date ______________________ 
 
______________________________________________________________________ 
Participant’s signature  
 
 
Right thumb fingerprinting   
 
 
 
 
I bore witness to the informed consent and that it was voluntary.  I can also verify that the participant or 
responsible party was informed of the details, risks and benefits of the assessment, and had the opportunity 
for their questions to be answered. 
 
 
 
 
____________________________  _____________ 
 
 
 
Signature of Witness 1  
 
 
Date    
 
 
 
 
____________________________  _____________ 
 
 
 
Signature of Witness 2 
 
 
Date   
 
 
Declaration by investigator  
I have adequately read, or born witness to the exact reading of the consent form, to the participant and the 
individual had the opportunity to ask questions.  I confirm that the individual freely gave their consent.  
 
Printed name of the member of the assessment team ______________________________________  
 
Signature of the member of the assessment team ____________________________________________  
 
 
 


46 
 
 
Note: Three copies will be made of this consent. One will remain with the patient or individual responsible 
for him or her, another will remain on file at the institution where the research takes place, and the third will 
remain with the coordinator of this assessment. 
   


47 
 
 
Appendix A2: Parental Permission Form for Parents of Patients Aged 5 Through 17 years.  (Flesh-
Kincaid 7.6)  
Project: Efficacy of High Total Dose of Primaquine to Prevent Plasmodium vivax Malaria Relapses in 
Cruzeiro do Sul, Brazil  
 
Purpose  
The Brazilian Ministry of Health is working with the Municipal Health Secretariat, State Department of 
Health of Acre, the Evandro Chagas Institute and the Centers for Disease Control and Prevention (CDC) in 
the United States of America. They are working on an evaluation on malaria treatment in Cruzeiro do Sul, 
Acre.  Malaria is a disease caused by a parasite that infects cells in your blood.   
 
The goal of this research is to see if the drugs used to treat malaria are working. We will evaluate treatment 
with chloroquine and primaquine for vivax malaria.  This is the kind of malaria most common in Brazil.  
 
This evaluation is being coordinated by Dr. Suiane Negreiros do Valle. She is a physician at the State 
Department of Health of Acre, works at the Hospital Regional do Jurua.   
 
We intend to include a total of 257 people aged 5 years and over in this assessment.  
 
If you agree, we intend to follow your child during the malaria treatment and for six months after the malaria 
treatment. We will collect blood samples during this time. This is to know if your child is free of malaria.  If 
you choose not to take part, your child will be treated in the same place with the same medications without 
any loss or penalty. 
 
Getting Started  
After the positive result for malaria vivax, we will place your child in one of three groups in this study. The 
decision to which group your child will enter will be random, which means it is by chance like flipping a 
coin.  One group will receive the three-day treatment with chloroquine under supervision and will take 
primaquine treatment at home for seven days.  This is the recommended practice by the Ministry of Health.  
Another group will receive chloroquine treatment for three days and primaquine for seven days under 
supervision.  The third group will also receive complete treatment under supervision but primaquine will be 
given for a total of 14 days under supervision. .  In this last group, the total dose of primaquine is higher than 


48 
 
 
the one currently recommended in Brazil, but it is within the recommendations by the World Health 
Organization. 
 
We will ask you some questions to know his/ her general health and condition of his/her current illness. We 
will ask you some questions to know his/her age and for how long your child has been sick.  You do not have 
to answer any questions you do not want.  In addition, you can decide at any time that you no longer want to 
take part in this survey.  
 
Your child’s care at the health clinic will not change if you choose not to respond or do not want to take part 
in this survey. We also want to examine your child and collect blood samples to confirm that he/ she has 
malaria.  We will collect a small amount of blood (about 7 ml, a tea spoon and a half) of blood from the vein 
in your child’s arm. This blood will be used to confirm the diagnosis of malaria.  It will also confirm your 
child has an active substance in his/ her blood to be able to tolerate the treatment with primaquine. We will 
do these tests right here in Cruzeiro do Sul.  After these initial tests, the blood will be stored for other 
laboratory tests to compare the response to the treatment in case your child has another malaria episode 
during the follow-up.  These new tests will be conducted at the Evandro Chagas Institute in Belém do Pará.  
A small part of the parasite material may be sent to the Centers for Disease Control and Prevention in the 
USA.   
 
After blood collection and confirmation of the diagnosis, we will immediately start treatment with 
chloroquine. The dose of medication and the number of days of treatment depend on your child’s weight.  
For the chloroquine dose, we follow the guidelines and recommendations of the Ministry of Health of Brazil.  
This means this medication is the same one that your child would be receiving even if she/ he did not take 
part in this evaluation.  Chloroquine should be taken for a total of three days.  We will ask you to come to 
this place to receive treatment from our hands. This is valid for all three study groups. We can go to his/ her 
home if you prefer.  Chloroquine is well tolerated.  It can cause nausea and some pain in the belly within the 
first few hours after taking it in some cases. There is also the risk of allergy to the medicines.  At each of 
these visits, three more visits after today, we need to collect four drops of blood from the tip of your child’s 
finger and also give him/ her chloroquine for two more days.  We will not need to collect blood from him/ 
her you tomorrow.   
 
When we get the results of your child’s laboratory tests, we will start primaquine treatment. This drug is 
complementary to chloroquine treatment.  It is also routinely indicated by the Brazilian Ministry of Health.  


49 
 
 
It is usually taken for a total of seven days. As part of this study, your child may be asked to take it for 14 
days. This, which is different than the recommendation in Brazil, is within the limits recommended by the 
World Health Organization. Depending on his/ her weight, she/ he may need to take primaquine for a few 
more days. He/ she will need to take the medicine either in front of the health professional or at home, 
depending on the study group.  Since it will not be necessary to collect blood all these days, you can decide if 
you prefer to come here.  We can also come to your child’s house to give the drug.   
 
Treatment and evaluation will be free of charge. The interview, examination, and blood collection will take 
about 30 minutes on the first visit.  It will take about 15 minutes on the next visits.  We recommend your 
child sleep under mosquito net with insecticide. This will protect him/ her from malaria.   
 
Follow-Up  
After treatment of the malaria, we would like to visit your child on a weekly basis for the first 28 days after 
malaria diagnosis.  Afterwards, we would like to visit your child once a month until six months are complete. 
It is important that you can take part in those visits.  Please let us know if you think that would not be 
possible.  During those visits, we will check his/ her health and collect two drops of blood from his/ her 
finger.  This is to see whether the malaria has been treated. If the malaria comes back, we will refer your 
child for treatment. The results of those tests are available the same day.  We will let you know the results.  
On the seventh day of follow-up, we need to collect a blood sample of more or less 2 mL (less than a 
teaspoon) from the vein in his/her arm.  This is to measure the levels of chloroquine.  In total, there will be 
10 samples from the fingertips and two blood samples from the vein in your arm.  We will give you a card 
with the visit scheduling.   
 
If your child is a girl aged more than 10 years old, inclusive, we will perform a urine or blood pregnancy test 
at the beginning of the study.  If your child of any age becomes pregnant while taking the medication, we 
will need to interrupt your participation.  Your child will be referred for treatment of malaria by a reference 
service here in Cruzeiro do Sul.  If she becomes pregnant after you have finished the drugs, we will follow 
your child as planned.   
 
If you or your child have any health problems or have any questions, please contact Dr. Suiane at the 
Hospital do Jurua in Cruzeiro do Sul.  You can also contact the person who is seen you today here or at the 
Sala de Estudos em Malaria na Santa Casa.  A member of the team will be able to assess you and your child 


50 
 
 
even if it is not the day of your child’s visit at the clinic.  The address of the hospital and sala de pesquisa 
are:  
Hospital Regional do Juruá   
 
 
Santa Casa de Misericórdia  
Rua 25 de agosto, 5121  
 
 
 
Rua Lauro Muller, 473  
BairroAeroporto Velho 
 
 
 
Bairro Manoel Terças  
Sala ao lado da CERIMAGEM  
Phone:  
(XX) XXXX XXXX  
 
(XX) XXXX XXXX 
 
 
Risks and Discomfort  
There is some discomfort and a small risk if you decide to take part in this study. Your child may have 
minimal pain when the blood is collected. Our team is well trained to avoid this.  In rare cases, there occurs 
light bleeding or bruising. If any injury occurs, we will take steps for your child to receive the proper care.  
We think it is very unlikely your child will have any harm.   
 
Benefits  
There will be direct and indirect benefit for your child upon taking part in this study. As part of this study, 
we will closely monitor your child with respect to his/ her disease. So, we will be able to offer your child any 
additional treatment very soon. His/ her participation will also assist the Brazilian malaria program to know 
if the malaria drugs are still working.   
 
Compensation  
You will not receive any compensation for participating in this study. However, we can reimburse you for 
food and transportation costs to attend the clinic visits.  If your child needs to be hospitalized, this will be 
done at a facility of the public health service in Brazil free of charge for you and your child.  Under the care 
of the study physician.   
 
Confidentiality  
We will keep your child’s information confidential to the full extent permitted by the law. His/ her name will 
be used only during the time she/he comes for her/his appointment or we visit your child’s house.  We will 
not share your child’s name with people outside of the study group or outside Cruzeiro do Sul. None of the 
reports from this study will contain your child’s name. Patient’s forms will be kept in locked cabinets.  Her/ 
his personal information will not be used for any purpose during this study.   


51 
 
 
 
Contact Information  
If you have any questions or feel your child has been harmed by being in this study, contact:  
 
• Dr. Suiane Negreiros do Valle, general coordinator of the project in Cruzeiro do Sul, phone (XX) 
XXXX XXXX.  
• Dr. Paola Marchesini, researcher, responsible for the follow-up of this study with the coordination of 
the Brazilian Malaria Program in Brasilia, (XX) XXXX XXXX.   
 
You can contact Dr. Arnaldo (information below) if you have any questions.  She is available to answer 
questions about your child’s rights as a participant. She is able to explain your rights as a patient in this 
study.  She is not directly involved in this study, but her role is to make sure your and your child’s rights are 
respected.   
 
Arnaldo Jorge Martins Filho 
Coordenador do Comitê de Ética em Pesquisa do Instituto Evandro Chagas - CEP/IEC 
Rodovia Br - 316, km 7 s/n 
67.030-000 Levilandia 
Ananindeua, Pará, Brasil 
Phone:  (XX) XXXX XXXX 
Voluntary participation, refusal and withdrawal  
Several aspects of this study are very important. Remember that:  
• You are free to decide if you want your child to take part in this study or not. If you decide not 
to take part, he/ she will receive the necessary free routine care and treatment, including for 
malaria. You or your child will not incur any penalty or loss for not taking part. 
• You are free to withdraw from this study at any time. That fact will not affect your child’s 
treatment or the care received. He/ she will still receive the routine free treatment for malaria.  
• In some situations, if your child develops side effects to the treatment or she/he gets malaria, we 
may need to withdraw your child from the study.   
• There is no cost to you or your child for taking part in this study.  
• You may let me know now if you have any questions with respect to the study.  You can also 
ask questions about your child’s participation.   
 


52 
 
 
Declaration of Consent  
Upon signing or providing a fingerprint indicating legal consent for the appropriate declaration, I agree that:  
• I have read this form or the form was read to me by someone else  
• I was able to ask questions about the study. My questions have been answered  
• I agree in a voluntary manner to participate in this study  
• I was informed that I have the right to withdraw from the study at any time. That will not affect the 
care given to me.   
 
 
Study participant’s name: ________________________________ Date ______________________ 
 
______________________________________________________________________ 
Guardian’s name  
 
_________________________________________________________________ 
Guardian’s signature   
 
 
Right thumb fingerprinting   
 
 
 
 
 
I bore witness to the informed parental permission and that it was voluntary.  I can also verify that the 
participant or responsible party was informed of the details, risks and benefits of the assessment, and had the 
opportunity for their questions to be answered. 
 
 
 
 
____________________________  _____________ 
 
 
 
Signature of Witness 1  
 
 
Date    
 
 
 
 
____________________________  _____________ 
 
 
 
Signature of Witness 2 
 
 
Date   
 


53 
 
 
 
 
Declaration by investigator  
I have adequately read, or born witness to the exact reading of the parental permission to the relative (mother 
or father) of the participant, or respective guardian, and the individual had the opportunity to ask questions.  I 
confirm that the individual freely gave their consent.  
 
Printed name of the member of the assessment team ______________________________________  
 
Signature of the member of the assessment team ____________________________________________  
 
 
Note: Three copies will be made of this consent. One will remain with the patient or individual responsible 
for him or her, another will remain on file at the institution where the research takes place, and the third will 
remain with the coordinator of this assessment. 
 
 


54 
 
 
Appendix B1: Assent Form (for participants aged 7–12, inclusive) (Flesh-Kincaid 3.8)  
 
Project: Efficacy of High Total Dose of Primaquine to Prevent Plasmodium vivax Malaria Relapses in 
Cruzeiro do Sul, Brazil  
 
The Secretariat that takes care of the health of the people in Cruzeiro do Sul will conduct a study.  This is to 
know if the drugs that are used to treat malaria are being good.  
 
Your parents / guardian let you take part.  I am asking you now if you want to take part. You are not required 
to take part.  Only if you want.   
 
As part of this study, you will be visited more often by a member of our team than if you were not part of it.  
You will receive the same routine malaria drugs.  
 
If you agree, you will receive two medications, one white and one orange.  They are not in liquid but in pill.  
Today we will also take a small amount of blood from your arm.  This is to do some tests. When we visit you 
to find out how you are.  We will also conduct further tests to see if you are still sick with malaria.  We will 
also want to know if the medicine is still in your blood, and how your body is reacting to the medicine.  If 
you are a woman 10 years of age or older, we will do a pregnancy test.  This is done in blood or urine.  We 
will inform your guardian of these results.  
 
You do not have to be afraid to take the sample.  The people who will take your blood are already used to 
doing this.  But it may hurt a little.  We will also take some blood from your fingers when you come to see 
us.  In one of these days, we will need to take blood from your arm again.  If you see or feel anything 
different after you take medicine tell mom or dad.  You can also tell the person who comes to see you.  If 
you already know how to call, you can even call us.  We are here to help you. 
 
If you no longer want to receive our visits, you can tell us.  This will not cause you any trouble.  
 
Do you understand what I said to you? You can ask your parents or me any questions.  
 
Want to be part of the project?  
 


55 
 
 
Appendix B2:  Assent Form (for participants aged 13–17, inclusive) (Flesh-Kincaid 4.6)  
 
Project: Efficacy of High Total Dose of Primaquine to Prevent Plasmodium vivax Malaria Relapses in 
Cruzeiro do Sul, Brazil  
 
 
The Acre Health Department is working with the Ministry of Health of Brazil and with international 
partners. We are conducting a study to evaluate the treatment of malaria here in Cruzeiro do Sul.  
 
Your parents / guardian agreed for to you take part.  I am asking you now if you want to take part. You are 
not required to take part if you do not want to.  
 
This study will offer you the same malaria medications you would receive if you were not in the study.  
However, you will be evaluated by our team more often than if you were not part of it.  
 
If you agree, you will receive the two drugs.  They are called chloroquine and primaquine.  You will need to 
come back here or we will come to you 13 more times in the next 6 months.  This is to see how you are 
feeling.  If you are not feeling well or have a fever, you may need to return more often. At each visit, we will 
collect a small amount of blood from your finger. This is to check if you are still sick and what type of 
malaria you have.  
 
Today and on the seventh day, we will also collect a small amount of blood from your arm.  This is to check 
the medicine in your blood.  It will also help us know how your body is reacting to the medicine. If you are a 
woman, we will do a pregnancy test.  This is done in blood or urine.  We will inform your parents of the 
result.  We will also ask your parents to save any left-over blood for future studies in malaria.   
 
It can hurt when we stick your finger or arm with the needle. An infection may occur. To prevent this, 
trained people will do the blood collection. Chloroquine can cause nausea and itchiness.  Primaquine can 
cause heartburn, vomiting and diarrhea. These symptoms are mild.  You may have severe symptoms, which 
is rare.  
 
There will be a person here every day to help you.  
 


56 
 
 
You may decide not to continue the study at any time and this will not cause you any problem.  
 
Do you have any questions regarding the study? You can ask your parents or me any questions.  
 
Do you want to be part of the project?  
 
 
 


57 
 
 
Annex C1. Authorization for storage of remaining samples (Participants aged 18 years and older and 
Parents of Participants aged five through 17 years) (Flesh-Kinkaid level 7.6) 
 
Invitation 
We would like to store what is left of the samples we collect during this study.  We will keep these samples 
at the Institutional biobank of the Evandro Chagas Institute.  This is part of the Brazilian Ministry of Health.  
A biobank is a place where we keep samples from people.  We respect people and the samples they give us 
to keep.  We need your free and informed consent to keep your/ your child’s samples.  We say the following 
things to make sure that you are taking part because you want to do so.  There is no penalty for not letting us 
keep your/ your child’s samples.  We want to make sure you know what we are doing and that you agree.  
 
Clarifications 
Evandro Chagas Institute is part of the Health Surveillance Secretariat of the Ministry of Health.  This is a 
place where we study ways to improve peoples’ lives.  Sometimes we discover new medicines and tests that 
help us know more about sicknesses and how to treat the people who have them.   
 
You and / or your child (or person for whom you are the legal guardian) are being asked to take part in a 
malaria study.  They and / or you have signed a consent form.  After the needed tests for your/ your child’s 
treatment or research are done, there may be some material left over.  This material is usually thrown away.  
However, we would like to ask you / your parents to let us store to keep it in the Evandro Chagas Institute for 
future use.  We will only do malaria studies with this material.   
 
We will be sure that the IEC and its partners will only use this material for malaria studies.  They will respect 
strict rules that show they respect life. We will be sure that all of your/ your child’s personal information is 
kept private. Your/ your child’s sample will be saved without your/ his/ her name on it.  We will keep a list 
of codes so that we know which sample is yours/ your child’s without using your name.  Only the people in 
charge of the bank will be able to see this list.   
 
If you wish, at any time, you will have access to the information generated with the use of your/ your child’s 
samples.  This includes the results from the research we have done.  To do that, you need to contact the 
Research Ethics Committee of the Evandro Chagas Institute.  The committee's contact information is listed 
below.  You may also request that your samples and information not be stored in the Biobank anymore.  If 


58 
 
 
you decide to not let us use your samples anymore, you must let us know in writing.  We will then destroy 
your/ your child’s samples according to the rules of the Evandro Chagas Institute.   
 
We remind you that your/ your child’s samples can also be thrown away if it is not possible for us to use in 
research for quality reasons.  The Instituto Evandro Chagas may also decide to end the biobank.  If this 
happens this happens, before we throw your/ your child’s sample away, we will offer it to at least two 
biobanks.  We will ask for your permission to do this if it happens.   
 
You will receive a copy of this consent form.  You can read it at any time.  You will not receive any 
payment.  You will also not have to pay anything for your samples to be stored in the bank of samples.   
 
When you take part in the biobank you have certain rights.  You can have your questions answered and get 
more information about these rights through the Research Ethics Committee of the Evandro Chagas Institute.  
This committee is responsible for monitoring the Biobank and evaluating the future research that will be 
happen there. 
 
The address of ethics committee is Rodovia BR-316, Km 07, Ananindeua, PA, Brazil.  It is opened from 
07:30 to 16:30.  If you prefer, the service can be reached at (68) 3214 2237.  The person responsible is Dr. 
Arnaldo Jorge Martins Filho.   
 
Declaration of Consent or Permission  
Upon signing or providing a fingerprint indicating legal consent for the appropriate declaration, I agree that:  
• I have read this form or the form was read to me by someone else  
• I was able to ask questions about the storage of blood. My questions have been answered  
• I agree in a voluntary manner to allow for the storage of my/my child’s blood.   
 
Study participant’s name: ________________________________ Date ______________________ 
 
______________________________________________________________________ 
Guardian’s name  
 
_________________________________________________________________ 
Patient’s or guardian’s signature   


59 
 
 
 
 
Right thumb fingerprinting   
 
 
 
 
 
I bore witness to the informed and voluntary consent.  I can also verify that the participant or responsible 
party was informed of the details, risks and benefits of the assessment, and had the opportunity for their 
questions to be answered. 
 
 
 
 
____________________________  _____________ 
 
 
 
Signature of Witness 1  
 
 
Date    
 
 
 
 
____________________________  _____________ 
 
 
 
Signature of Witness 2 
 
 
Date   
 
 
Declaration by investigator  
I have adequately read, or born witness to the exact reading of the consent form, to the participant or relative 
(mother or father) of the participant, or respective guardian, and the individual had the opportunity to ask 
questions. I confirm that the individual freely gave their consent.  
 
Printed name of the member of the assessment team ______________________________________  
 
Signature of the member of the assessment team ____________________________________________  
 
 
 
 
 
 


60 
 
 
Annex C2. Assent Form for Storage of Remaining Samples (Participants 7 to 12 years) 
 
Study design: Efficacy of High Total Dose of Primaquine to Prevent Plasmodium vivax Malaria 
Relapses in Cruzeiro do Sul, Brazil  
 
 
Invitation 
You are part of a malaria study.  As part of this study, we will collect some blood from you.  Sometimes 
there is blood left over after the tests.  Usually, we throw away what is left over.  If there is blood left over, 
we want to keep it.  We would keep it at Evandro Chagas Institute of the Ministry of Health.   
 
Clarifications 
At the Evandro Chagas Institute, we do studies.  These studies help people live better lives.   
 
We want to keep the remaining blood to help in other studies in malaria.  We asked your parents, and they 
said it is okay to keep it.  They know who to talk to if they have questions.  We are asking you if it is also 
okay with you.   
 
If you let us keep the blood, no one will know it is yours except the people responsible for the blood at 
Evandro Chagas.  It is okay if you do not want us to keep the blood.  You will be treated the same if you say 
yes or if you say no.   
 
Do you understand what I said to you? You can ask your parents or me any questions. 
 
Is it okay with you if we keep the blood that is left over from your tests?   
 
 
 


61 
 
 
Annex C3. Assent Form for Storage of Remaining Samples (Participants 13 to 17 years)  
 
Study design: Efficacy of High Total Dose of Primaquine to Prevent Plasmodium vivax Malaria 
Relapses in Cruzeiro do Sul, Brazil  
 
Invitation 
You are part of the malaria study.  For this, you do blood tests.  Sometimes there is blood left over after the 
tests.  Usually, we throw away this blood.  If there is blood left over, we want to keep it instead of throwing 
it away.  We would keep it at Evandro Chagas Institute of the Ministry of Health. 
 
Clarifications 
At the Evandro Chagas Institute, we do studies.  These studies to help people live better lives.   
 
You are taking part in a malaria study.  For this, we will collect some blood.  We want to use whatever is left 
to use in other studies.  Only studies on malaria would be done.  We asked your parents, and they said it is 
okay to keep it.  They know who to talk to if they have questions.  We are asking you if it is also okay with 
you. 
 
If you let us keep the blood, no one will know it is yours except the people at Evandro Chagas.  It is okay if 
you do not want us to keep the blood.  You will be treated the same if you say yes or if you say no.   
 
Do you understand what I said to you? You can ask your parents or me any questions. 
 
Is it okay with you if we keep the blood that is left over to do future studies?   


62 
 
 
Annex D. Antimalarial drugs that should not be used in the 30 days prior to enrolment and also 
during the study period  
 
• 
Chloroquine (except for the prescribed period) 
• 
Amodiaquine 
• 
Qinino, quinidine 
• 
Mefloquine, lumefantrine 
• 
Artemisinin and its derivatives 
• 
Proguanil 
• 
Sulfadoxine, sulfamethoxazole (bactrim), dapsone 
• 
Primaquina (except for the prescribed period) 
• 
Atovaquone 
• 
Antibiotics: tetracycline, doxycycline, erythromycin, azytromycin, clindamycin, 
rifampicin 
• 
Pentamidine


63 
 
 
Annex E: Patient form  
 
IDENTIFICATION 
(This page is not typed into the database.) 
Patient number 
Necklace label 
Patient name 
 
  If child, <18 years 
Mother's name 
 
Father's name 
 
Name of the person in charge 
 
Address with reference 
points how to get 
 
Best(s) phone number(s) to 
talk to the patient 
 
Cost of transportation per 
day (round trip) 
(real) 
 
Reminder (mark the steps taken): 
☐ Sorting sheet ok   
☐ Consent to the patient 
☐ Harvest the blood of Day 0 (admission). 
 


 
 
64 
Clinical Form  
 
CLINICAL HISTORICAL 
Patient number 
Necklace label 
Date (dd/mm/aaa) 
and time (e.g., 
09:00, 15:00) of 
admission   
__ __ /__ __ /2018 __ __: __ __ hours 
Treatment group 
☐Group 1 (7 days, patient unsupervised) 
☐Group 2 (7 days, patient with supervision) 
☐Group 3 (14 days, patient with supervision) 
 
Health center 
☐1. Hospital Regional do Juruá  
☐2. Posto 25 de Agosto   
☐  3. Aeroporto Velho 
☐  4. Cruzeirinho 
☐  5. Other      If another, which one? ___________________________ 
Sex 
☐  1. Male 
☐  2. Female 
Date of birth 
(dd/mm/aaaa) 
  __ __ /__ __ /__ __ __ __ 
Consent and 
assents 
☐ Informed consent of the study delivered  
☐ Informed consent for sample storage delivered 
Study assent 
  
☐Does not apply (adult patient)  
 
☐ Delivered 
Assent for sample storage  
☐Does not apply (adult patient)  
 
☐ Delivered 
*Continue on the next page* 
 


 
 
65 
CLINICAL HISTORICAL 
When did you start showing 
symptoms of the current 
illness? 
_____/_____/2018 
Have you had a fever in the 
last 48 hours? 
☐ Yes 
          If yes, fever duration: _______ days 
☐ No 
What other symptoms do 
you experience during your 
current illness? 
 
(Mark all possible.) 
☐ Headache 
☐ Vomiting 
☐Calf pain 
☐ Chills 
☐ Diarrhea 
☐ Dark urine 
☐ Sweats 
☐ General weakness 
 
☐ Other 
If others, which ones? 
 
 
 
  
 
 
 
 
 
 
Have you taken any 
medication for this disease 
or taken any medication in 
the last 30 days? 
 
If the patient has been in 
use or recent use of 
antimalarials (see list of 
antimalarials), 
terminate. 
☐ Yes  
     If so, what medications?  Dose?  When is it? 
☐ No 
 
Medication 
Dose 
Start and end 
 
 
 
 
 
 
 
 
 
Do you suffer from the 
following chronic diseases: 
kidneys diseases, HIV or 
AIDS, tuberculosis and or 
malnutrition? 
☐ Yes 
If so, which ones? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
☐ No 
 
 
 
 
 
 
 
 
 
 
 
 
If yes, terminate 
 
Do you have any allergies 
(especially allergies to 
medications)? 
 
☐ Yes 
 
If so, which ones?    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
☐ No 
 
 
 
 
 
 
 
 
 
If allergy to chloroquine or primaquine (severe allergy), 
END. In the case of only mild itching (itching) with the 
use of chloroquine, discuss with Dr. Suiane). 
 
*Continue on the next page* 
 


 
 
66 
PHYSICAL EXAMINATION (DAY 0) 
Axillar temperature 
__________  
Systolic blood pressure 
 ______________ mmHg 
Diastolic blood pressure 
 ______________ mmHg 
Weight 
_________  
Heart rate 
____________ beats per minute 
Respiratory rate 
__________  
 
 
Normal 
Abnormal 
Mental state 
☐ Awake and oriented 
☐ Sleepy, but oriented 
☐ Disoriented 
☐ Comatose 
Chest 
☐ Normal breathing 
☐ Breathing difficulty 
☐Increased breathing (>20 
movements per minute) 
Abdomen 
☐ Not distended and pain-
without on palpation 
☐ Pain on palpation 
☐ Distended 
☐ Painful and distended 
Extremities (lower) 
☐ No cyanosis and/or edema 
☐ Cyanosis 
☐ Edema 
☐ Cyanosis and edema 
Jaundice 
☐ Absent 
☐ This 
 
**In the event of any marking on the right column (abnormal), 
discuss with Dr. Suiane patient inclusion* 
 


 
 
67 
Hemoglobin 
______________ mg/dl 
 
 
 
 
 
  
 
Pregnancy test performed in 
women aged 10 to 49 years 
☐It does not 
apply 
*Man; woman <10 or >49 years 
☐ Blood 
 
☐ Urine 
 
☐They have not 
*If positive or not performed in women aged 
10 to 49 years, terminate 
Pregnancy test result 
☐ Negative 
 
☐ Positive 
*END* 
☐ Refused 
*END* 
 
  
 
G6PD 
______________  U/g Hb 
*If less than  7.0  UI/g Hb, 
shut  down  
 
*Continue on the next page* 
 
 


 
 
68 
LABORATORY TEST (DAY 0) 
First blade reading  
(Mark only one response) 
☐Only P. vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found       *END* 
☐Another Which? ________________  *Close* 
First reading asexual parasitemia 
____________________ /microliter 
First reading gametocytemia 
____________________ /microliter 
Second blade reading  
(Mark only one response) 
☐Only P.  vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found       *END* 
☐Another Which? ________________ *Close* 
Second reading asexual parasitemia 
____________________ /microliter 
Second reading gametocytemia 
____________________ /microliter 
Comparison between first and second readings 
  Difference=   
 
 
 
  
_______________- _______________= __________________ 
Higher asexual 
parasitemia 
Smallest asexual 
parasitemia 
 
 
Difference > Minor parasitemia? 
☒ Yes ☐     No 
 
        2 
 
Or species discrepancy?  
If 'yes', ask for third reading 
Third blade reading 
(Mark only one response) 
☐Only P. vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found       *END* 
☐Another Which? ________________ *Close* 
Third reading asexual parasitemia 
____________________ /microliter 
Third reading gametocytemia 
____________________ /microliter 
Geometric mean of the closest values of asexual 
parasitemia (if positive) (____________________ 
and __________________)  
____________________ 
/microliter 


 
 
69 
 
Write All the Doses of Medication 
(Chloroquine and Primaquine) 
For Information Only 
 
Group number __________  
 
Patient weight  
_______ kg  
Chloroquine (150 mg per tablet) 
 
D0: ______ tablets 
 
D1: ______ tablets   
 
D2: ______ tablets   
Primaquine (_______mg per tablet) 
 _______ treatment days 
Primaquine  
 
1st dose    _______ tablets 
 
2nd dose _______ tablets 
 
3rd dose _______ tablets 
 
4th to 7th doses _______ tablets 
 
≥8th doses _______ tablets 
 
 
Note to supervising nurse.  
Check this information. 
 


 
 
70 
Treatment 
Day 0 (Chloroquine, hemoglobin level) 
1st dose of chloroquine 
______ 150 mg tablet (s) 
Time of first attempt for 1st dose* 
 __ __ __ __ __ (ex. 09:00, 18:00) 
Vomit in 30 minutes? 
☐ Yes 
☐ No 
If vomiting in the first 30 min, time of the second 
attempt for the 1st dose* 
__ __ : __ __ 
Vomit in 30 minutes? 
 
If vomiting on the second attempt, END 
☐ Yes 
☐ No 
Did the patient receive paracetamol in this 
consultation? 
☐ Yes 
☐ No 
Observation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Responsible for the visit: 
________________    
Reminder (mark the steps taken): 
☐Slides 
☐ Filter paper 
☐ Hemoglobin 
☐ Testes G6PD (EDTA tube) 
☐Pregnancy test (leave blank if not applicable) 
☐ Schedule return 
☐ Fill in the returns on the patient card (pencil) 
 


 
 
71 
Return 
NURSE DAY 1 (Chloroquine)  
Date of visit 
__ __ /__ __ /2018  
Axillary temperature (°C) 
____________  
Since your last appointment you had:  
Fever? 
☐ Yes 
☐ No 
Headache? 
☐ Yes 
☐ No 
Calf pain? 
☐ Yes 
☐ No 
Dark urine? 
☐ Yes 
☐ No 
Vomiting? 
☐ Yes 
☐ No 
Diarrhea? 
☐ Yes 
☐ No 
Itching? 
☐ Yes 
☐ No 
Red spots on the body (cutaneous erythema)? 
☐ Yes 
☐ No 
Menstrual delay (women 10 to 49 years)? 
☐ Yes 
☐No☐ Does not apply 
If yes, pregnancy test result 
☐ Negative 
 
☐ Positive 
*END* 
☐ Refused 
*END* 
Any other symptoms? 
☐ Yes 
☐ No 
If so, which one?  
Have you taken any other medication besides 
the treatment given here? 
☐ Yes 
☐ No 
In the case of another medicinal product, name 
and quantity and start and end date 
 
If you experience any symptoms, treatment, or use of medication, 
warn Dr. Suiane*** 
Patient felt better, equal, or worse? 
☐ Better 
☐ Equal 
☐ Worse 
*Continues next page*  
 


 
 
72 
2nd dose of chloroquine 
_____ 150 mg tablet (s) 
Time of first attempt for dose 
__ __ : __ __ 
Vomit in 30 minutes? 
☐ Yes 
☐ No 
If vomiting in the first 30 min, time of the 
second attempt for the dose 
__ __ : __ __ 
Vomit in 30 minutes? 
 
If vomiting on the second attempt, END 
☐ Yes 
☐ No 
 
Day 1 condition of the patient 
☐ Continue 
☐ Exclude 
☐ Left 
☐ Abandoned 
☐ Follow-up termination 
Responsible for the visit: 
___________________________   
 
Observation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reminder (mark the steps taken): 
☐ Check G6PD (give primaquine if normal) 
☐ Schedule return  
 
 


 
 
73 
 
Return 
NURSE DAY 2 (Chloroquine)   
Date of visit 
__ __ /__ __ /2018  
Axillary temperature (°C) 
____________  
Since your last appointment you had:  
Fever?  
☐ Yes 
☐ No 
Headache? 
☐ Yes 
☐ No 
Calf pain? 
☐ Yes 
☐ No 
Dark urine? 
☐ Yes 
☐ No 
Vomiting?  
☐ Yes 
☐ No 
Diarrhea? 
☐ Yes 
☐ No 
Itching? 
☐ Yes 
☐ No 
Red spots on the body (cutaneous erythema)?  
☐ Yes 
☐ No 
Menstrual delay (women 10 to 49 years)?  
☐ Yes 
☐No☐ Does not apply 
If yes, pregnancy test result  
☐ Negative 
 
☐ Positive 
*END* 
☐ Refused 
*END* 
Any other symptoms? 
☐ Yes 
☐ No 
If so, which one? _______________________________ 
Have you taken any other medication besides 
the treatment given here? 
☐ Yes 
☐ No 
In the case of another medicinal product, name 
and quantity and start and end date 
 
If you experience any symptoms, treatment, or use of medication, 
warn Dr. Suiane*** 
Patient felt better, equal, or worse? 
☐ Better 
☐ Equal 
☐ Worse 
 
*Continue on the next page* 
 


 
 
74 
LABORATORY TEST (DAY 2) 
First blade reading  
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________ *Close* 
First reading asexual parasitemia 
____________________ /microliter 
First reading gametocytemia 
____________________ /microliter 
Second blade reading  
(Mark only one response) 
☐Only P.  vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________*Close* 
Second reading asexual parasitemia 
____________________ /microliter 
Second reading gametocytemia 
____________________ /microliter 
Comparison between first and second readings 
  Difference=   
 
 
 
  
_______________- _______________= __________________ 
Higher asexual 
parasitemia 
Smallest asexual 
parasitemia 
 
 
Difference > Minor parasitemia? 
☐ Yes ☐     No 
 
        2 
 
Or species discrepancy?  
If 'yes', ask for third reading 
Third blade reading 
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________ *Close* 
Third reading asexual parasitemia 
____________________ /microliter 
Third reading gametocytemia 
____________________ /microliter 
Geometric mean of the closest values of asexual 
parasitemia (if positive) (____________________ 
and __________________)  
____________________ 
/microliter 
**Treatment on the next page** 
 


 
 
75 
3rd dose of chloroquine 
______ 150 mg tablet (s) 
Time of first attempt for dose 
__ __ : __ __ 
Vomit in 30 minutes? 
☐ Yes 
☐ No 
If vomiting in the first 30 min, time of the 
second attempt for the dose 
__ __ : __ __ 
Vomit in 30 minutes? 
 
If vomiting on the second attempt, END 
☐ Yes 
☐ No 
 
Day 2 patient condition 
☐ Continue 
☐ Exclude 
☐ Left 
☐ Abandoned 
☐ Follow-up termination 
Responsible for the visit: 
___________________________   
 
Observation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reminder (mark the steps taken): 
☐ Slides 
☐ Check G6PD (give primaquine if normal) 
☐ Schedule return 
 


 
 
76 
Return  
NURSE DAY 3 
Date of visit 
__ __ /__ __ /2018  
Axillary temperature (°C) 
____________  
Since your last appointment you had:  
Fever?  
☐ Yes 
☐ No 
Headache? 
☐ Yes 
☐ No 
Calf pain? 
☐ Yes 
☐ No 
Dark urine? 
☐ Yes 
☐ No 
Vomiting?  
☐ Yes 
☐ No 
Diarrhea? 
☐ Yes 
☐ No 
Itching? 
☐ Yes 
☐ No 
Red spots on the body (cutaneous erythema)?  
☐ Yes 
☐ No 
Menstrual delay (women 10 to 49 years)?  
☐ Yes 
☐No☐ Does not apply 
If yes, pregnancy test result  
☐ Negative 
 
☐ Positive 
*END* 
☐ Refused 
*END* 
Any other symptoms? 
☐ Yes 
☐ No 
If so, which one? ____________________________ 
Have you taken any other medication besides 
the treatment given here? 
☐ Yes 
☐ No 
In the case of another medicinal product, name 
and quantity and start and end date 
 
If you experience any symptoms, treatment, or use of medication, 
warn Dr. Suiane*** 
Patient felt better, equal, or worse? 
☐ Better 
☐ Equal 
☐ Worse 
 
*Continue on the next page* 
 


 
 
77 
LABORATORY TEST (DAY 3) 
First blade reading  
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________ *Close* 
First reading asexual parasitemia 
____________________ /microliter 
First reading gametocytemia 
____________________ /microliter 
Second blade reading  
(Mark only one response) 
☐Only P.  vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________*Close* 
Second reading asexual parasitemia 
____________________ /microliter 
Second reading gametocytemia 
____________________ /microliter 
Comparison between first and second readings 
  Difference=   
 
 
 
  
_______________- _______________= __________________ 
Higher asexual 
parasitemia 
Smallest asexual 
parasitemia 
 
 
Difference > Minor parasitemia? 
☐ Yes ☐     No 
 
        2 
 
Or species discrepancy?  
If 'yes', ask for third reading 
Third blade reading 
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________ *Close* 
Third reading asexual parasitemia 
____________________ /microliter 
Third reading gametocytemia 
____________________ /microliter 
Geometric mean of the closest values of asexual 
parasitemia (if positive) (____________________ 
and __________________)  
____________________ 
/microliter 
*Continue on the next page* 
 


 
 
78 
Day 3 patient condition 
☐ Continue 
☐ Exclude 
☐ Left 
☐ Abandoned 
☐ Follow-up termination 
Responsible for the visit: 
__________________________   
 
Observation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reminder (mark the steps taken): 
☐ Slides 
☐ Check G6PD (give primaquine if normal) 
☐ Schedule return 
 


 
 
79 
 
Return  
DAY 7 (Chloroquine level) 
Date of visit 
__ __ /__ __ /2018 
Axillary temperature (°C) 
____________  
Since your last appointment you had:  
Fever?  
☐ Yes 
☐ No 
Headache? 
☐ Yes 
☐ No 
Calf pain? 
☐ Yes 
☐ No 
Dark urine? 
☐ Yes 
☐ No 
Vomiting?  
☐ Yes 
☐ No 
Diarrhea? 
☐ Yes 
☐ No 
Itching? 
☐ Yes 
☐ No 
Red spots on the body (cutaneous erythema)?  
☐ Yes 
☐ No 
Menstrual delay (women 10 to 49 years)?  
☐ Yes 
☐No☐ Does not apply 
If yes, pregnancy test result  
☐ Negative 
 
☐ Positive 
*END* 
☐ Refused 
*END* 
Any other symptoms? 
☐ Yes 
☐ No 
If so, which one? __________________________ 
Have you taken any other medication besides 
the treatment given here? 
☐ Yes 
☐ No 
In the case of another medicinal product, name 
and quantity and start and end date 
 
If you experience any symptoms, treatment, or use of medication, 
warn Dr. Suiane*** 
Patient felt better, equal, or worse? 
☐ Better 
☐ Equal 
☐ Worse 
Continue on the next page* 
 


 
 
80 
LABORATORY TEST (DAY 7) 
First blade reading  
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________ *Close* 
First reading asexual parasitemia 
____________________ /microliter 
First reading gametocytemia 
____________________ /microliter 
Second blade reading  
(Mark only one response) 
☐Only P.  vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________ *Close* 
Second reading asexual parasitemia 
____________________ /microliter 
Second reading gametocytemia 
____________________ /microliter 
Comparison between first and second readings 
  Difference=   
 
 
 
  
_______________- _______________= __________________ 
Higher asexual 
parasitemia 
Smallest asexual 
parasitemia 
 
 
Difference > Minor parasitemia? 
☐ Yes ☐     No 
 
        2 
 
Or species discrepancy?  
If 'yes', ask for third reading 
Third blade reading 
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________ *Close* 
Third reading asexual parasitemia 
____________________ /microliter 
Third reading gametocytemia 
____________________ /microliter 
Geometric mean of the closest values of asexual 
parasitemia (if positive) (____________________ 
and __________________)  
____________________ /microliter 
*Continue on the next page* 
 


 
 
81 
Day 7 patient condition 
☐ Continue 
☐ Exclude 
☐ Left 
☐ Abandoned 
☐ Follow-up termination 
Responsible for the visit: 
__________________________    
Chloroquine 
________________   mg/dl 
Observation 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Reminder (mark the steps taken): 
☐ Chloroquine level (heparin tube) 
☐ Slides 
☐ Check G6PD (give primaquine if normal) 
☐Schedule return 
☐ Schedule doses of Primaquine 
 


 
 
82 
Return  
DAY 14(Hemoglobin level) 
Date of visit 
__ __ /__ __ /2018  
Axillary temperature (°C) 
____________  
Since your last appointment you had:  
Fever?  
☐ Yes 
☐ No 
Headache? 
☐ Yes 
☐ No 
Calf pain? 
☐ Yes 
☐ No 
Dark urine? 
☐ Yes 
☐ No 
Vomiting?  
☐ Yes 
☐ No 
Diarrhea? 
☐ Yes 
☐ No 
Itching? 
☐ Yes 
☐ No 
Red spots on the body (cutaneous erythema)?  
☐ Yes 
☐ No 
Menstrual delay (women 10 to 49 years)?  
☐ Yes 
☐No☐ Does not apply 
If yes, pregnancy test result  
☐ Negative 
 
☐ Positive 
*END* 
☐ Refused 
*END* 
Any other symptoms? 
☐ Yes 
☐ No 
If so, which one? __________________________ 
Have you taken any other medication besides 
the treatment given here? 
☐ Yes 
☐ No 
In the case of another medicinal product, name 
and quantity and start and end date 
 
If you experience any symptoms, treatment, or use of medication, 
warn Dr. Suiane*** 
Patient felt better, equal, or worse? 
☐ Better 
☐ Equal 
☐ Worse 
*Continue on the next page* 
 
 


 
 
83 
LABORATORY TEST (DAY 14) 
First blade reading  
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________ *Close* 
First reading asexual parasitemia 
____________________ /microliter 
First reading gametocytemia 
____________________ /microliter 
Second blade reading  
(Mark only one response) 
☐Only P.  vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________ *Close* 
Second reading asexual parasitemia 
____________________ /microliter 
Second reading gametocytemia 
____________________ /microliter 
Comparison between first and second readings 
  Difference=   
 
 
 
  
_______________- _______________= __________________ 
Higher asexual 
parasitemia 
Smallest asexual 
parasitemia 
 
 
Difference > Minor parasitemia? 
☐ Yes ☐     No 
 
        2 
 
Or species discrepancy?  
If 'yes', ask for third reading 
Third blade reading 
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________ *Close* 
Third reading asexual parasitemia 
____________________ /microliter 
Third reading gametocytemia 
____________________ /microliter 
Geometric mean of the closest values of asexual 
parasitemia (if positive) (____________________ 
and __________________)  
____________________ 
/microliter 
*Continue on the next page* 
 


 
 
84 
Day 14 patient condition 
☐ Continue 
☐ Exclude 
☐ Left 
☐ Abandoned 
☐ Follow-up termination 
Responsible for the visit: 
__________________________   
 
Hemoglobin 
________________   mg/dl 
 
Observation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reminder (mark the steps taken): 
☐ Blood for hemoglobin level 
☐ Blood for microscopy (slides) 
☐ Check G6PD (give primaquine if normal) 
☐Schedule return 
☐ Schedule doses of Primaquine 
 


 
 
85 
Return  
DAY 21 
Date of visit 
__ __ /__ __ /2018  
Axillary temperature (°C) 
____________  
Since your last appointment you had:  
Fever?  
☐ Yes 
☐ No 
Headache? 
☐ Yes 
☐ No 
Calf pain? 
☐ Yes 
☐ No 
Dark urine? 
☐ Yes 
☐ No 
Vomiting?  
☐ Yes 
☐ No 
Diarrhea? 
☐ Yes 
☐ No 
Itching? 
☐ Yes 
☐ No 
Red spots on the body (cutaneous erythema)?  
☐ Yes 
☐ No 
Menstrual delay (women 10 to 49 years)?  
☐ Yes 
☐No☐ Does not  apply 
If yes, pregnancy test result  
☐ Negative 
 
☐ Positive 
*END* 
☐ Refused 
*END* 
Any other symptoms? 
☐ Yes 
☐ No 
If so, which one?  
Have you taken any other medication besides 
the treatment given here? 
☐ Yes 
☐ No 
In the case of another medicinal product, name 
and quantity and start and end date 
 
If you experience any symptoms, treatment, or use of medication, 
warn Dr. Suiane*** 
Patient felt better, equal, or worse? 
☐ Better 
☐ Equal 
☐ Worse 
 
*Continue on the next page*  
 


 
 
86 
LABORATORY TEST (DAY 21) 
First blade reading  
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum *END* 
☐P falciparum and  mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________ *Close* 
First reading asexual parasitemia 
____________________ /microliter 
First reading gametocytemia 
____________________ /microliter 
Second blade reading  
(Mark only one response) 
☐Only P.  vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________ *Close* 
Second reading asexual parasitemia 
____________________ /microliter 
Second reading gametocytemia 
____________________ /microliter 
Comparison between first and second readings 
  Difference=   
 
 
 
  
_______________- _______________= __________________ 
Higher asexual 
parasitemia 
Smallest asexual 
parasitemia 
 
 
Difference > Minor parasitemia? 
☐ Yes ☐     No 
 
        2 
 
Or species discrepancy?  
If 'yes', ask for third reading 
Third blade reading 
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum  *END* 
☐P falciparum and  mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________  *Close* 
Third reading  asexual parasitemia 
____________________ /microliter 
Third reading  gametocytemia 
____________________ /microliter 
Mean geomistrica of the mostclose values 
ofasexual parasitemia (if positive) 
(____________________ and 
__________________)  
____________________ 
/microliter 
*Continue on the next page* 
 


 
 
87 
Day 21  patient  condition 
☐ Continue 
☐ Exclude 
☐ Left 
☐ Abandoned 
☐ Follow-up termination 
Responsible for the visit: 
__________________________   
 
Observation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reminder (mark the steps taken): 
☐ Slides) 
☐ Check G6PD (give primaquine is normal) 
☐ Schedule return Schedule primaquine doses 
☐ 
 


 
 
88 
Return  
DAY 28 (Hemoglobinlevel) 
Date of visit 
__ __ /__ __ /2018  
Axillary temperature(theC) 
____________  
Since your last appointment you had:  
Fever?  
☐ Yes 
☐ No 
Headache? 
☐ Yes 
☐ No 
Calf  pain? 
☐ Yes 
☐ No 
Dark urine? 
☐ Yes 
☐ No 
Vomiting?  
☐ Yes 
☐ No 
Diarrhea? 
☐ Yes 
☐ No 
Itching? 
☐ Yes 
☐ No 
Red spots on the body (cutaneous erythema)?  
☐ Yes 
☐ No 
Menstrual delay (women 10 to 49 years)?  
☐ Yes 
☐No☐ Does  not  apply 
If yes, pregnancy test result  
☐ Negative 
 
☐ Positive 
*END* 
☐ Refused 
*END* 
Any other symptoms? 
☐ Yes 
☐ No 
If so, which one? __________________________ 
Have you taken any other medication besides 
the treatment given here? 
☐ Yes 
☐ No 
In the case of another medicinal product, name 
and quantity and start and end date 
 
If you experience any symptoms, treatment, or use of medication, 
warn Dr. Suiane*** 
Patient felt better, equal, or worse? 
☐ Better 
☐ Equal 
☐ Worse 
 
*Continue on the next page*  
 


 
 
89 
LABORATORY TEST (DAY 28) 
First blade reading  
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum  *END* 
☐P falciparum and  mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________  *Close* 
First reading  asexual parasitemia 
____________________ /microliter 
First reading gametocytemia 
____________________ /microliter 
Second blade reading  
(Mark only one response) 
☐Only P.  vivax 
☐Only P. falciparum  *END* 
☐P falciparum and  mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________  *Close* 
Second reading asexual parasitemia 
____________________ /microliter 
Second reading gametocytemia 
____________________ /microliter 
Comparison between first and second readings 
  Difference=   
 
 
 
  
_______________- _______________= __________________ 
Higher asexual 
parasitemia 
Smallest asexual 
parasitemia 
 
 
Difference > Minor parasitemia? 
☐ Yes ☐     No 
 
        2 
 
Or species discrepancy?  
If 'yes', ask for third reading 
Third blade reading 
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum  *END* 
☐P falciparum and  mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________  *Close* 
Third reading  sexual parasitemia 
____________________ /microliter 
Third reading gametocytemia 
____________________ /microliter 
Geometric mean of the closest values of asexual 
parasitemia (if positive) 
(____________________ and 
__________________)  
____________________ 
/microliter 
*Continue on the next page* 
 


 
 
90 
Hemoglobin 
________________   mg/dl 
 
Have you finished all doses of your treatment with 
primaquine  (7 days) ? (Group 1 only) 
☐ Yes 
☐ No 
☐ Does not apply (Groups 2 and 3)  
 
Day 28 patient  condition 
☐ Continue 
☐ Exclude 
☐ Left 
☐ Abandoned 
☐ Follow-up termination 
Responsible for the visit: 
__________________________   
 
Observation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reminder (mark the steps taken): 
☐ Blood for hemoglobin level 
☐ Slides 
☐ Check G6PD (give primaquine is normal) 
☐ Schedule return 
☐Check end of  primaquina 
 


 
 
91 
Return  
DAY 56 / MONTH 2 
Date of visit 
__ __ /__ __ /2018  
Axillary temperature(theC) 
____________  
Since your last appointment you had:  
Fever?  
☐ Yes 
☐ No 
Headache? 
☐ Yes 
☐ No 
Calf  pain? 
☐ Yes 
☐ No 
Dark urine? 
☐ Yes 
☐ No 
Vomiting?  
☐ Yes 
☐ No 
Diarrhea? 
☐ Yes 
☐ No 
Itching? 
☐ Yes 
☐ No 
Red spots on the body (cutaneous erythema)?  
☐ Yes 
☐ No 
Menstrual delay (women 10 to 49 years)?  
☐ Yes 
☐No☐ Does  not  apply 
If yes, pregnancy test result  
☐ Negative 
 
☐ Positive 
*END* 
☐ Refused 
*END* 
Any other symptoms? 
☐ Yes 
☐ No 
If so, which one? ___________________________  
Have you taken any other medication besides 
the treatment given here? 
☐ Yes 
☐ No 
In the case of another medicinal product, name 
and quantity and start and end date 
 
If you experience any symptoms, treatment, or use of medication, 
warn Dr. Suiane*** 
Patient felt better, equal, or worse? 
☐ Better 
☐ Equal 
☐ Worse 
 
*Continue on the next page*  
 


 
 
92 
LABORATORY TEST (DAY 56 /  MES 2) 
First blade reading  
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum  *END* 
☐P falciparum and  mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________  *Close* 
First reading  asexual parasitemia 
____________________ /microliter 
First reading gametocytemia 
____________________ /microliter 
Second blade reading  
(Mark only one response) 
☐Only P.  vivax 
☐Only P. falciparum  *END* 
☐P falciparum and  mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________  *Close* 
Second reading asexual parasitemia 
____________________ /microliter 
Second reading gametocytemia 
____________________ /microliter 
Comparison between first and second readings 
  Difference=   
 
 
 
  
_______________- _______________= __________________ 
Higher asexual 
parasitemia 
Smallest asexual 
parasitemia 
 
 
Difference > Minor parasitemia? 
☐ Yes ☐     No 
 
        2 
 
Or species discrepancy?  
If 'yes', ask for third reading 
Third blade reading 
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum  *END* 
☐P falciparum and  mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________  *Close* 
Third reading  asexual parasitemia 
____________________ /microliter 
Third reading  gametocytemia 
____________________ /microliter 
Geometric mean of the closest values of asexual 
parasitemia (if positive) 
(____________________ and 
__________________)  
____________________ 
/microliter 
*Continue on the next page* 
 


 
 
93 
Day 56 / month 2 patient  condition 
☐ Continue 
☐ Exclude 
☐ Left 
☐ Abandoned 
☐ Follow-up termination 
Responsible for the visit: 
__________________________   
 
Observation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reminder (mark the steps taken): 
☐ Slides 
☐ Check that the primaquine doses are complete (if G6PD normal) 
☐ Schedule return 
 


 
 
94 
Return  
DAY 84 / MONTH 3 
Date of visit 
__ __ /__ __ /2018  
Axillary temperature(theC) 
____________  
Since your last appointment you had:  
Fever?  
☐ Yes 
☐ No 
Headache? 
☐ Yes 
☐ No 
Calf  pain? 
☐ Yes 
☐ No 
Dark urine? 
☐ Yes 
☐ No 
Vomiting?  
☐ Yes 
☐ No 
Diarrhea? 
☐ Yes 
☐ No 
Itching? 
☐ Yes 
☐ No 
Red spots on the body (cutaneous erythema)?  
☐ Yes 
☐ No 
Menstrual delay (women 10 to 49 years)?  
☐ Yes 
☐No☐ Does  not  apply 
If yes, pregnancy test result  
☐ Negative 
 
☐ Positive 
*END* 
☐ Refused 
*END* 
Any other symptoms? 
☐ Yes 
☐ No 
If so, which one? ____________________________ 
Have you taken any other medication besides 
the treatment given here? 
☐ Yes 
☐ No 
In the case of another medicinal product, name 
and quantity and start and end date 
 
If you experience any symptoms, treatment, or use of medication, 
warn Dr. Suiane*** 
Patient felt better, equal, or worse? 
☐ Better 
☐ Equal 
☐ Worse 
 
*Continue on the next page*  
 


 
 
95 
LABORATORY TEST (DAY 84 /  MES 3) 
First blade reading  
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum  *END* 
☐P falciparum and  mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________  *Close* 
First reading  asexual parasitemia 
____________________ /microliter 
First reading gametocytemia 
____________________ /microliter 
Second blade reading  
(Mark only one response) 
☐Only P.  vivax 
☐Only P. falciparum  *END* 
☐P falciparum and  mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________  *Close* 
Second reading asexual parasitemia 
____________________ /microliter 
Second reading gametocytemia 
____________________ /microliter 
Comparison between first and second readings 
  Difference=   
 
 
 
  
_______________- _______________= __________________ 
Higher asexual 
parasitemia 
Smallest asexual 
parasitemia 
 
 
Difference > Minor parasitemia? 
☐ Yes ☐     No 
 
        2 
 
Or species discrepancy?  
If 'yes', ask for third reading 
Third blade reading 
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum  *END* 
☐P falciparum and  mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________  *Close* 
Third reading  asexual parasitemia 
____________________ /microliter 
Third reading  gametocytemia 
____________________ /microliter 
Geometric mean of the closest values of asexual 
parasitemia (if positive) 
(____________________ and 
__________________)  
____________________ 
/microliter 
*Continue on the next page* 
 


 
 
96 
Day 84 / month 3 patient  condition 
☐ Continue 
☐ Exclude 
☐ Left 
☐ Abandoned 
☐ Follow-up termination 
Responsible for the visit: 
__________________________   
 
Observation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reminder (mark the steps taken): 
☐ Slides 
☐ Schedule return 
 
 


 
 
97 
Return  
DAY 112 / MONTH 4 
Date of visit 
__ __ /__ __ /20____  
Axillary temperature(theC) 
____________  
Since your last appointment you had:  
Fever?  
☐ Yes 
☐ No 
Headache? 
☐ Yes 
☐ No 
Calf  pain? 
☐ Yes 
☐ No 
Dark urine? 
☐ Yes 
☐ No 
Vomiting?  
☐ Yes 
☐ No 
Diarrhea? 
☐ Yes 
☐ No 
Itching? 
☐ Yes 
☐ No 
Red spots on the body (cutaneous erythema)?  
☐ Yes 
☐ No 
Menstrual delay (women 10 to 49 years)?  
☐ Yes 
☐No☐ Does  not  apply 
If yes, pregnancy test result  
☐ Negative 
 
☐ Positive 
*END* 
☐ Refused 
*END* 
Any other symptoms? 
☐ Yes 
☐ No 
If so, which one? _________________________ 
Have you taken any other medication besides 
the treatment given here? 
☐ Yes 
☐ No 
In the case of another medicinal product, name 
and quantity and start and end date 
 
If you experience any symptoms, treatment, or use of medication, 
warn Dr. Suiane*** 
Patient felt better, equal, or worse? 
☐ Better 
☐ Equal 
☐ Worse 
 
*Continue on the next page* 
 
 


 
 
98 
LABORATORY TEST (DAY 112 /  MONTH 4) 
First blade reading  
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________ *Close* 
First reading asexual parasitemia 
____________________ /microliter 
First reading gametocytemia 
____________________ /microliter 
Second blade reading  
(Mark only one response) 
☐Only P.  vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________ *Close* 
Second reading asexual parasitemia 
____________________ /microliter 
Second reading gametocytemia 
____________________ /microliter 
Comparison between first and second readings 
  Difference=   
 
 
 
  
_______________- _______________= __________________ 
Higher asexual 
parasitemia 
Smallest asexual 
parasitemia 
 
 
Difference > Minor parasitemia? 
☐ Yes ☐     No 
 
        2 
 
Or species discrepancy?  
If 'yes', ask for third reading 
Third blade reading 
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________ *Close* 
Third reading asexual parasitemia 
____________________ /microliter 
Third reading gametocytemia 
____________________ /microliter 
Geometric mean of the closest values of asexual 
parasitemia (if positive (____________________ 
and __________________)  
____________________ 
/microliter 
*Continue on the next page* 
 


 
 
99 
Day 112 / month 4 patient condition 
☐ Continue 
☐ Exclude 
☐ Left 
☐ Abandoned 
☐ Follow-up termination 
Responsible for the visit: 
__________________________   
 
Observation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reminder (mark the steps taken): 
☐ Slides 
☐Schedule Return 
 


 
 
100
Return  
DAY 140 / MONTH 5 
Date of visit 
__ __ /__ __ /20____  
Axillary temperature (°C) 
____________  
Since your last appointment you had:  
Fever?  
☐ Yes 
☐ No 
Headache? 
☐ Yes 
☐ No 
Calf pain? 
☐ Yes 
☐ No 
Dark urine? 
☐ Yes 
☐ No 
Vomiting?  
☐ Yes 
☐ No 
Diarrhea? 
☐ Yes 
☐ No 
Itching? 
☐ Yes 
☐ No 
Red spots on the body (cutaneous erythema)?  
☐ Yes 
☐ No 
Menstrual delay (women 10 to 49 years)?  
☐ Yes 
☐No☐ Does not apply 
If yes, pregnancy test result  
☐ Negative 
 
☐ Positive 
*END* 
☐ Refused 
*END* 
Any other symptoms? 
☐ Yes 
☐ No 
If so, which one? ____________________________ 
Have you taken any other medication besides 
the treatment given here? 
☐ Yes 
☐ No 
In the case of another medicinal product, name 
and quantity and start and end date 
 
If you experience any symptoms, treatment, or use of medication, 
warn Dr. Suiane*** 
Patient felt better, equal, or worse? 
☐ Better 
☐ Equal 
☐ Worse 
 
*Continue on the next page* 
 
 


 
 
101
LABORATORY TEST (DAY 140 / MONTH 5) 
First blade reading  
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________ *Close* 
First reading asexual parasitemia 
____________________ /microliter 
First reading gametocytemia 
____________________ /microliter 
Second blade reading  
(Mark only one response) 
☐Only P.  vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________ *Close* 
Second reading asexual parasitemia 
____________________ /microliter 
Second reading gametocytemia 
____________________ /microliter 
Comparison between first and second readings 
  Difference=   
 
 
 
  
_______________- _______________= __________________ 
Higher asexual 
parasitemia 
Smallest asexual 
parasitemia 
 
 
Difference > Minor parasitemia? 
☐ Yes ☐     No 
 
        2 
 
Or species discrepancy?  
If 'yes', ask for third reading 
Third blade reading 
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum  *END* 
☐P falciparum and  mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________ *Close* 
Third reading asexual parasitemia 
____________________ /microliter 
Third reading gametocytemia 
____________________ /microliter 
Geometric mean of the closest values of asexual 
parasitemia (if positive (____________________ 
and __________________)  
____________________ 
/microliter 
*Continue on the next page* 
 


 
 
102
Day 140 / month 5 patient condition 
☐ Continue 
☐ Exclude 
☐ Left 
☐ Abandoned 
☐ Follow-up termination 
Responsible for the visit: 
__________________________   
 
Observation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reminder (mark the steps taken): 
☐ Slides 
☐ Schedule return 
 
 


 
 
103
Return  
DAY 168 / MONTH 6 
Date of visit 
__ __ /__ __ /20____  
Axillary temperature (°C) 
____________  
Since your last appointment you had:  
Fever?  
☐ Yes 
☐ No 
Headache? 
☐ Yes 
☐ No 
Calf pain? 
☐ Yes 
☐ No 
Dark urine? 
☐ Yes 
☐ No 
Vomiting?  
☐ Yes 
☐ No 
Diarrhea? 
☐ Yes 
☐ No 
Itching? 
☐ Yes 
☐ No 
Red spots on the body (cutaneous erythema)?  
☐ Yes 
☐ No 
Menstrual delay (women 10 to 49 years)?  
☐ Yes 
☐No☐ Does not  apply 
If yes, pregnancy test result  
☐ Negative 
 
☐ Positive 
*END* 
☐ Refused 
*END* 
Any other symptoms? 
☐ Yes 
☐ No 
If so, which one? ______________________________ 
Have you taken any other medication besides 
the treatment given here? 
☐ Yes 
☐ No 
In the case of another medicinal product, name 
and quantity and start and end date 
 
If you experience any symptoms, treatment, or use of medication, 
warn Dr. Suiane*** 
Patient felt better, equal, or worse? 
☐ Better 
☐ Equal 
☐ Worse 
 
*Continue on the next page*  
 


 
 
104
LABORATORY TEST (DAY 168 /  MONTH 6) 
First blade reading  
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________  *Close* 
First reading asexual parasitemia 
____________________ /microliter 
First reading gametocytemia 
____________________ /microliter 
Second blade reading  
(Mark only one response) 
☐Only P.  vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________  *Close* 
Second reading asexual parasitemia 
____________________ /microliter 
Second reading gametocytemia 
____________________ /microliter 
Comparison between first and second readings 
  Difference=   
 
 
 
  
_______________- _______________= __________________ 
Higher asexual 
parasitemia 
Smallest asexual 
parasitemia 
 
 
Difference > Minor parasitemia? 
☐ Yes ☐     No 
 
        2 
 
Or species discrepancy?  
If 'yes', ask for third reading 
Third blade reading 
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________  *Close* 
Third reading asexual parasitemia 
____________________ /microliter 
Third reading gametocytemia 
____________________ /microliter 
Geometric mean of the closest values of asexual 
parasitemia (if positive) (____________________ 
and __________________)  
____________________ 
/microliter 
*Continue on the next page* 
 


 
 
105
Day 168 / month 6 patient condition 
☐ Continue 
☐ Exclude 
☐ Left 
☐ Abandoned 
☐ Follow-up termination 
Responsible for the visit: 
__________________________   
 
Observation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reminder (mark the steps taken): 
☐ Slides 
☐ Schedule return  
 
 


 
 
106
FINAL PATIENT OUTCOME 
Outcome date ______/_____/20____  
Outcome follow-up day ______ 
☐ Completed 168 days of follow-up 
☐ Discontinued follow-up before 168 days with parasitemia or other therapeutic failure 
☐ Revoked consent or nod 
☐ Loss of follow-up 
☐ Interrupted medication due to adverse effects 
☐ Other. What? __________________________________________________________________ 
 
OBSERVATION OF THE OUTCOME 
(FILLED OUT BY NURSE) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Responsible for the visit: 
________________________    
 
 


 
 
107
EXTRA DAY FOR SYMPTOM AFTER DAY 3 
Study day 
______ DAY 
Date of visit 
__ __ /__ __ /20___  
Axillary temperature(theC) 
____________  
Since your last appointment you had:  
Fever?  
☐ Yes 
☐ No 
Headache? 
☐ Yes 
☐ No 
Calf pain? 
☐ Yes 
☐ No 
Dark urine? 
☐ Yes 
☐ No 
Vomiting?  
☐ Yes 
☐ No 
Diarrhea? 
☐ Yes 
☐ No 
Itching? 
☐ Yes 
☐ No 
Red spots on the body (cutaneous erythema)?  
☐ Yes 
☐ No 
Menstrual delay (women 10 to 49 years)?  
☐ Yes 
☐No☐ Does not apply 
If yes, pregnancy test result  
☐ Negative 
 
☐ Positive 
*END* 
☐ Refused 
*END* 
Any other symptoms? 
☐ Yes 
☐ No 
If so, which one? ______________________________ 
Have you taken any other medication besides 
the treatment given here? 
☐ Yes 
☐ No 
In the case of another medicinal product, name 
and quantity and start and end date 
 
If you experience any symptoms, treatment, or use of medication, 
warn Dr. Suiane*** 
Patient felt better, equal, or worse? 
☐ Better 
☐ Equal 
☐ Worse 
 
*Continue on the next page*  
 


 
 
108
EXTRA DAY LABORATORY EXAMINATION SYMPTOM 
(____DAY) 
First blade reading  
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________  *Close* 
First reading asexual parasitemia 
____________________ /microliter 
First reading gametocytemia 
____________________ /microliter 
Second blade reading  
(Mark only one response) 
☐Only P.  vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________ *Close* 
Second reading asexual parasitemia 
____________________ /microliter 
Second reading gametocytemia 
____________________ /microliter 
Comparison between first and second readings 
  Difference=   
 
 
 
  
_______________- _______________= __________________ 
Higher asexual 
parasitemia 
Smallest asexual 
parasitemia 
 
 
Difference > Minor parasitemia? 
☐ Yes ☐     No 
 
        2 
 
Or species discrepancy?  
If 'yes', ask for third reading 
Third blade reading 
(Mark only one response) 
☐Only P. Vivax 
☐Only P. falciparum *END* 
☐P falciparum and mixed vivax P   *END* 
☐ No parasites found        
☐Another Which? ________________  *Close* 
Third reading asexual parasitemia 
____________________ /microliter 
Third reading gametocytemia 
____________________ /microliter 
Geometric mean of the closest values of asexual 
parasitemia (if positive) (____________________ 
and __________________)  
____________________ 
/microliter 
 
*Continue on the next page* 
 


 
 
109
Patient's condition 
☐ Continue 
☐ Exclude 
☐ Left 
☐ Abandoned 
☐ Follow-up termination 
 
Chloroquine (if visited between Day 8 and Day 
28only for special  reasons) 
________________   mg/dl 
 
Observation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conduct 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Responsible for the visit: 
________________________    
 
Reminder (mark the steps taken): 
☐ Spoon filter paper if positive blade 
☐ Collect blood (heparin tube, green) for chloroquine if Day 28 or 
earlier 
☒ Schedule return 


 
 
110 
Annex F. Adverse Events Form  
 
Patient ID 
 
 
 
 
 
Chave para ficha de EA 
Severity 
1 = Mild (Grade 1): Signal or symptom awareness easily tolerated 
2 = Moderate (Grade 2): Discomfort sufficient to cause interference with normal activity 
3 = Severe (Grade 3): Incapacitating with incapacity for work or carrying out habitual activity 
4 = At risk of death (Grade 4): Patient at risk of death at the time of the event, or requires hospitalization or prolongation of hospitalization; cause a persistent or 
significant disability; result in congenital anomaly or birth defect 
5 = Death (Grade 5) 
Study drug 
related?  1=Definitly not  
2=Improbably related 
3=Possibly related  
4= Probably related  
5= Definitly related  
Outcome 
1=Total recovery 
2=Patient not recovered 
yest 
3=Worsening  
4=Permanet sequalae 
5=Death 
6=On going 
7=Unknown  
Action take 
1=No measure 
2=Dose adjustment or 
temporarily suspended 
3=Permanent withdrawal 
of drugs 
4=Concomitant drug 
given  
5=No therapy given  
6= Hospitalization 
 
Number of adverse 
events 
 
 
Data:  
 
 
/ 
 
 
 
/ 
 
 
 
 
 
 
 
 
Diagnosis  
________________________________________________________________________________________________
_______ 
 
Onset date 
 
 
/ 
 
 
 
/ 
 
 
 
End date 
 
 
/ 
 
 
 
/ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Severity ☐  1     ☐  2     ☐  3     ☐  4     ☐  5      
Related to the study drug  ☐  1     ☐  2     ☐  3     ☐  4     ☐  5      
Result ☐  1     ☐  2     ☐  3     ☐  4     ☐  5    ☐  6     
☐  7       
Treatment ☐  1     ☐  2     ☐  3     ☐  4     ☐  5    ☐  
6  
Treatment 
administered  
☐  Yes   
☐  No    Specify  _____________________________________________________________________________ 


 
 
111 
Was this a severe 
one? 
☐  Yes    
☐  No    
 
 
Number of adverse 
event 
 
 
Reporting date 
 
 
/ 
 
 
 
/ 
 
 
 
 
 
 
 
 
Diagnosis  ________________________________________________________________________________________________
_______ 
Onset date 
 
 
/ 
 
 
 
/ 
 
 
 
End date 
 
 
/ 
 
 
 
/ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Severity ☐  1     ☐  2     ☐  3     ☐  4     ☐  5      
Related to study drug ☐  1     ☐  2     ☐  3     ☐  4     ☐  5      
Outcome 
☐  1     ☐  2     ☐  3     ☐  4     ☐  5    ☐  6     
☐  7       
Treatment  ☐  1     ☐  2     ☐  3     ☐  4     ☐  5    ☐  
6  
Treatment 
administered 
☐  Yes   
☐  No    Specify:  _____________________________________________________________________________ 
Was this a severe 
one? 
☐  Yes    
☐  No    
 
 
Number of adverse 
event 
 
 
Reporting date 
 
 
/ 
 
 
 
/ 
 
 
 
 
 
 
 
 
Diagnosis  ________________________________________________________________________________________________
_______ 
Onset date 
 
 
/ 
 
 
 
/ 
 
 
 
End date 
 
 
/ 
 
 
 
/ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Severity ☐  1     ☐  2     ☐  3     ☐  4     ☐  5      
Related to study drug ☐  1     ☐  2     ☐  3     ☐  4     ☐  5      


 
 
112 
Outcome ☐  1     ☐  2     ☐  3     ☐  4     ☐  5    ☐  6     
☐  7       
Treatment  ☐  1     ☐  2     ☐  3     ☐  4     ☐  5    ☐  
6  
Treatment 
administered 
☐  Yes   
☐  No    Specify:  _____________________________________________________________________________ 
Was this a severe 
one? 
☐  Yes    
☐  No    
 
 
 
 
Form filled by  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
/  
 
 
/  
 
 
 
 
 
 
Name 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signature 
 
 
 
 
 
 
 
 
 


 
 
113
Annex G. Randomization table. 
 
Order 
Arm 
1 Grupo 3 
2 Grupo 3 
3 Grupo 2 
4 Grupo 1  
5 Grupo 2 
6 Grupo 3 
7 Grupo 1  
8 Grupo 3 
9 Grupo 2 
10 Grupo 2 
11 Grupo 1  
12 Grupo 3 
13 Grupo 1  
14 Grupo 3 
15 Grupo 1  
16 Grupo 2 
17 Grupo 2 
18 Grupo 3 
19 Grupo 3 
20 Grupo 1  
21 Grupo 2 
22 Grupo 2 
23 Grupo 3 
24 Grupo 3 
25 Grupo 2 
26 Grupo 1  
27 Grupo 2 
28 Grupo 3 
29 Grupo 2 
30 Grupo 3 
31 Grupo 1  
32 Grupo 2 
33 Grupo 1  
34 Grupo 3 
35 Grupo 3 
36 Grupo 2 
37 Grupo 2 
38 Grupo 2 
39 Grupo 3 
40 Grupo 2 
41 Grupo 3 
42 Grupo 1  
43 Grupo 3 
44 Grupo 1  
45 Grupo 3 
46 Grupo 2 
47 Grupo 2 
48 Grupo 2 
49 Grupo 3 
50 Grupo 1  
51 Grupo 3 
52 Grupo 1  
53 Grupo 2 
54 Grupo 2 
55 Grupo 3 
56 Grupo 1  
57 Grupo 2 
58 Grupo 3 
59 Grupo 3 
60 Grupo 3 
61 Grupo 2 
62 Grupo 1  
63 Grupo 2 
64 Grupo 2 
65 Grupo 3 
66 Grupo 1  
67 Grupo 3 
68 Grupo 2 
69 Grupo 2 
70 Grupo 2 
71 Grupo 3 
72 Grupo 1  
73 Grupo 3 
74 Grupo 1  
75 Grupo 2 
76 Grupo 3 
77 Grupo 3 
78 Grupo 2 
79 Grupo 3 
80 Grupo 3 
81 Grupo 2 
82 Grupo 1  
83 Grupo 2 
84 Grupo 1  
85 Grupo 1  
86 Grupo 2 
87 Grupo 2 
88 Grupo 3 
89 Grupo 3 
90 Grupo 1  
91 Grupo 1  
92 Grupo 2 
93 Grupo 3 
94 Grupo 2 
95 Grupo 3 
96 Grupo 2 
97 Grupo 1  
98 Grupo 3 
99 Grupo 3 
100 Grupo 2 
101 Grupo 1  
102 Grupo 3 
103 Grupo 3 
104 Grupo 2 
105 Grupo 2 
106 Grupo 1  
107 Grupo 1  
108 Grupo 2 
109 Grupo 3 
110 Grupo 2 
111 Grupo 3 
 


 
 
114
112 Grupo 3 
113 Grupo 2 
114 Grupo 1  
115 Grupo 1  
116 Grupo 3 
117 Grupo 2 
118 Grupo 3 
119 Grupo 1  
120 Grupo 2 
121 Grupo 2 
122 Grupo 3 
123 Grupo 1  
124 Grupo 1  
125 Grupo 3 
126 Grupo 2 
127 Grupo 2 
128 Grupo 3 
129 Grupo 1  
130 Grupo 2 
131 Grupo 2 
132 Grupo 3 
133 Grupo 3 
134 Grupo 2 
135 Grupo 2 
136 Grupo 3 
137 Grupo 1  
138 Grupo 3 
139 Grupo 3 
140 Grupo 2 
141 Grupo 3 
142 Grupo 2 
143 Grupo 1  
144 Grupo 1  
145 Grupo 2 
146 Grupo 3 
147 Grupo 2 
148 Grupo 1  
149 Grupo 3 
150 Grupo 3 
151 Grupo 1  
152 Grupo 2 
153 Grupo 3 
154 Grupo 1  
155 Grupo 2 
156 Grupo 3 
157 Grupo 2 
158 Grupo 1  
159 Grupo 2 
160 Grupo 3 
161 Grupo 1  
162 Grupo 2 
163 Grupo 3 
164 Grupo 3 
165 Grupo 2 
166 Grupo 1  
167 Grupo 2 
168 Grupo 1  
169 Grupo 2 
170 Grupo 3 
171 Grupo 3 
172 Grupo 1  
173 Grupo 3 
174 Grupo 2 
175 Grupo 2 
176 Grupo 3 
177 Grupo 3 
178 Grupo 3 
179 Grupo 2 
180 Grupo 1  
181 Grupo 2 
182 Grupo 1  
183 Grupo 2 
184 Grupo 3 
185 Grupo 2 
186 Grupo 3 
187 Grupo 1  
188 Grupo 1  
189 Grupo 2 
190 Grupo 2 
191 Grupo 3 
192 Grupo 3 
193 Grupo 3 
194 Grupo 1  
195 Grupo 3 
196 Grupo 2 
197 Grupo 2 
198 Grupo 1  
199 Grupo 3 
200 Grupo 2 
201 Grupo 3 
202 Grupo 1  
203 Grupo 2 
204 Grupo 2 
205 Grupo 1  
206 Grupo 2 
207 Grupo 1  
208 Grupo 3 
209 Grupo 3 
210 Grupo 1  
211 Grupo 2 
212 Grupo 3 
213 Grupo 3 
214 Grupo 2 
215 Grupo 3 
216 Grupo 2 
217 Grupo 3 
218 Grupo 1  
219 Grupo 2 
220 Grupo 2 
221 Grupo 2 
222 Grupo 3 
223 Grupo 1  
224 Grupo 3 
225 Grupo 2 
226 Grupo 2 
227 Grupo 3 
228 Grupo 1  
229 Grupo 3 
230 Grupo 3 
231 Grupo 2 
232 Grupo 3 
233 Grupo 2 
234 Grupo 1  
235 Grupo 1  
236 Grupo 3 
237 Grupo 2 
238 Grupo 1  
239 Grupo 3 
240 Grupo 2 


 
 
115
241 Grupo 3 
242 Grupo 1  
243 Grupo 2 
244 Grupo 2 
245 Grupo 3 
246 Grupo 1  
247 Grupo 1  
248 Grupo 3 
249 Grupo 2 
250 Grupo 3 
251 Grupo 2 
252 Grupo 1  
253 Grupo 1  
254 Grupo 2 
255 Grupo 3 
256 Grupo 2 
257 Grupo 3 
 
 


 
 
1
 
Statistical Plan  
 
Efficacy of High Total Dose of Primaquine to Prevent Plasmodium vivax 
Malaria Relapses in Cruzeiro do Sul, Brazil  
 
Statistical Analysis Plan  
 
 
Principal investigators: Suiane da Costa Negreiros, Giselle Maria Rachid Viana, Alexandre Macedo de 
Oliveira  
 
Co-investigators: Nathália Nogueira Chamma-Siqueira, Sarah-Blythe Ballard, Samela Farias, Sandro 
Patroca da Silva, Stella M. Chenet, Eduardo José Melo dos Santos, Luann Wendel Pereira de Sena, Flávia 
Póvoa da Costa, Amanda Gabryelle Nunes Cardoso Mello, Paola Barbosa Marchesini, Cassio Roberto 
Leonel Peterka  
 
Analysis plan developed by Alexandre Macedo de Oliveira and Nathália Nogueira Chamma-Siqueira, study 
investigators  
 
Analysis plan revision supported by John Williamson, statistician, Malaria Branch, Division of Parasitic 
Diseases and Malaria, CDC.   
 
Date: April 2020  
 
 
CDC IRB: #7061.0  
Clinicaltrials.gov registration number: NCT03610399  
 
Funder: Latin America and Caribbean Regional Malaria Program  
 


 
 
2
 
Table of contents 
1. 
Introduction 
     
 
 
 
 
 
 
 
 
 
Error! 
Bookmark not defined. 
1.1. 
Design overview ................................................................................................................. Error! 
Bookmark not defined. 
1.2. 
Sample size ......................................................................................................................... Error! 
Bookmark not defined. 
1.3. 
Randomization and allocation ............................................................................................ Error! 
Bookmark not defined. 
2. 
Purpose of the analysis plan  
 
 
 
 
 
 
 
Error! 
Bookmark not defined. 
3. 
Definitions and variables of interest  
 
 
 
 
 
 
Error! 
Bookmark not defined. 
3.1. 
Definitions .......................................................................................................................... Error! 
Bookmark not defined. 
3.2. 
Variables of interest ............................................................................................................ Error! 
Bookmark not defined. 
3.3. 
Morbidity endpoint definitions ........................................................................................... Error! 
Bookmark not defined. 
3.4. 
Outcome definitions ............................................................................................................ Error! 
Bookmark not defined. 
4. 
Study endpoints 
 
 
 
 
 
 
 
 
 
Error! 
Bookmark not defined. 
4.1. 
Primary efficacy outcome ................................................................................................... Error! 
Bookmark not defined. 
4.2. 
Secondary efficacy outcomes ............................................................................................. Error! 
Bookmark not defined. 
5. 
Statistical methods 
 
 
 
 
 
 
 
 
 
Error! 
Bookmark not defined. 
5.1. 
Data cleaning and descriptive statistics .............................................................................. Error! 
Bookmark not defined. 
5.2. 
Analytical statistics ............................................................................................................. Error! 
Bookmark not defined. 
6. 
Adverse events 
 
 
 
 
 
 
 
 
 
Error! 
Bookmark not defined.   
7. 
Limitations 
 
 
 
 
 
 
 
 
 
 
Error! 
Bookmark not defined. 
8. 
References 
 
 
 
 
 
 
 
 
 
 
Error! 
Bookmark not defined. 
9. 
Appendix A. Randomization table 
 
 
 
 
 
 
 
Error! 
Bookmark not defined. 
10. 
Appendix B. List of anticipated tables and figures for data analysis. 
 
 
Error! 
Bookmark not defined. 
11. 
Appendix C. CONSORT checklist of information to include when reporting a trial 
Error! 
Bookmark not defined. 


 
 
3
 
 
 


 
 
4
Introduction  
Design overview  
This is a three-arm randomized clinical trial to evaluate the therapeutic efficacy of chloroquine (CQ) and 
primaquine in the treatment of Plasmodium vivax malaria in Cruzeiro do Sul, State of Acre, Brazil using 
three primaquine schemes.  Patients in group 1 are instructed to take primaquine as non-observed therapy for 
a total dose of 3.5 mg/kg over seven days (0.5 mg/kg/day), while those in group 2 receive the same regimen, 
but under directly observed therapy.  Participants in group 3 receive directly observed primaquine therapy 
for 14 days (0.5 mg/kg/day) aiming for a total dose of 7.0 mg/kg. We will compare treatment response 
between groups 1 and 3, and groups 2 and 3.  
 
Sample size  
Seventy-four participants in groups 2 and 3 are needed to compare an expected and estimated day 168 
recurrence-free proportion of 70% in group 2 and 90% in group 3 (power= 90% and level of significance= 
5%); estimates based on prior studies in the region.1,2 Similarly, to compare a day 168 recurrence-free 
proportion of 90% (group 3) and 60% (group 1), we need 39 participants in each group, which will be 
increased to 50 participants per prior recommendations.3 We will add 30% in each study group to account for 
loss to follow-up and reached a sample size of 96 participants in groups 2 and 3, and 65 in group 1; 257 
participants in total.  
 
Randomization and allocation  
The randomization sequence (Appendix A) present in the protocol was computer-generated by one of the 
investigators at the Centers for Disease Control and Prevention using SAS. The result of this process is a 
sequential enrollment list respecting the desired sample size per study groups. Since two study teams are 
involved in patient enrollment, one team will start from the top of the list and the other from the bottom.  
Regular meeting between the two nurses of the study teams will allow for checking if the total of 257 study 
participants in total are enrolled, so enrollment can be stopped.   
 
The field study coordinator will assemble participant’s clinical forms for both study teams and put them 
sequentially with a blank opaque cover on top of each one.  At the time of enrollment, field study member 
will pick the top of their respective team pile and have the pre-selected study group for each new participant.  


 
 
5
Up to that moment, neither the field study member, nor the participant will have knowledge of study group 
assignment.  
 
Purpose of the analysis plan  
The purpose of this document is to outline the statistical analysis plan for this study, which is primarily 
meant to compare the efficacy of the higher dose of primaquine to prevent P. vivax recurrences during a 168-
day follow-up.  Additionally, we will also evaluate co-variables and the outcome.   
 
Definitions and variables of interest  
Definitions  
P. vivax infection  
P. vivax infection will be defined as presence of P. vivax parasites in peripheral blood collected at protocol 
scheduled visits or in case of symptomatic patients using microscopic examination.  In case of positive 
samples, malaria species will be identified (P. vivax, P. falciparum, others) and quantified according to 
parasite characteristics and laboratory standard operating procedures developed by study investigators.   
 
Molecular genotyping  
We will use microsatellite genotyping to differentiate homologous day 0–day of recurrence parasites from 
heterologous ones as homologous recurrences most likely reflect relapses or recrudescences and, therefore, 
more accurately relate to drug efficacy. Day 0 and day of recurrence samples processed in parallel will allow 
investigators to classify their haplotypes profiles; paired samples with at least one microsatellite difference 
are considered heterologous haplotypes, while all others homologous.2,4 In addition to the main outcome of 
interest, we will evaluate treatment efficacy and comparisons considering homologous recurrences only.   
 
Variables of interest  
We plan to collect demographic (e..g, sex, age, place of residence, etc), clinical (presence of fever at 
enrolment, etc), and parasitological (parasite density at enrollment, time for parasite clearance, etc) variables 
in the course of this study using standard clinical forms.  
 
We will evaluate different variables for their role as confounders and effect modifiers in our analysis and use 
appropriate statistical methods to account for those. These variables are primaquine initiation date, glucose 


 
 
6
6-phosphate dehydrogenase (G6PD) activity, sex, place of residence (rural vs. urban), and cytochrome 2PD6 
phenotype, for example.   
 
Morbidity endpoint definitions  
Outcome definitions  
Treatment efficacy will be evaluated using a combination of clinical and laboratory information.3 There are 
different approaches to determine outcomes in antimalarial efficacy trials. We chose the simpler 
classification adapted for P. vivax studies.  Day 28 treatment failure is defined as (1) clinical deterioration 
due to P. vivax illness requiring hospitalization in the presence of parasitemia, (2) presence of parasitemia 
and fever (axillary temperature ≥37.5 °C) on any day between days 3 and 28; or (3) presence of parasitemia 
on any day between days 7 and 28, irrespective of clinical condition.  
 
Since we are also interested in recurrences that occur as a result of failure to the primaquine component, we 
will also monitor the resurgence of parasitemia between days 28 and 168, with or without fever.  Those cases 
will be classified as extended follow-up failure. A day 28 adequate clinical and parasitological response 
(ACPR) includes participants who do not meet criteria for day 28 treatment failure.  We will also determine 
day 168 ACPR as patients who do not meet any failure criteria during the entire follow-up (168 days).  
 
The clinical and parasitological diagnosis of malaria is the main focus of this study and the main outcome of 
interest.  We will, however, replicate the per-protocol analysis (details below) considering genotyping 
information comparing the genotype of parasites from day 0 (enrollment) and day of failure considering only 
homologous recurrences as failures.  The secondary analysis will be done in the same way as for the primary 
one.  
 
Study endpoints  
Primary efficacy outcome  
The primary outcome is development of clinical or parasitological P. vivax infection during the follow-up 
period (168 days).  
 


 
 
7
Secondary efficacy outcomes  
The secondary outcome is the molecular-corrected P. vivax infection (homologous recurrences) during 
follow-up (168 days).   
 
Statistical methods  
Data cleaning and descriptive statistics  
Clinical forms will be double entered in databases.  Data will be compared and cleaned before proceeding to 
data analysis.  Variables will be checked for the presence of outliers, using tabulation, frequency distribution, 
and box plots. We will provide and display descriptive summaries for each of the primary and secondary 
variables. In general, tables will summarize data by study group. Continuous, quantitative, variable 
summaries will include the number of subjects (n) with non-missing values, mean, standard deviation (SD), 
median, and range (minimum and maximum), unless otherwise specified. Categorical, qualitative, variable 
summaries will include the frequency and percentage of participants in each category per study group.   
 
Means, SD, and any other statistics other than quartiles will be reported to one decimal place greater than the 
original unit of measure. Quartiles, such as median, or minimum and maximum will use the same number of 
decimal places as the original data. Estimated parameters, not on the same scale as raw observations (e.g., 
regression coefficients) will be reported to three significant figures.   
 
In general, we will consider the total number of participants in the analysis set for the study groups as the 
denominator for the percentage calculation.  All statistical tests will be based on a 2-sided test at the 
significance level of 0.05 and 95% confidence intervals, unless otherwise specified. Finally, we will use 
graphical and table-format presentation to show results from the statistical analyses.  
 
We will use SAS™ version 9.4 (SAS Institute, Cary, North Carolina, USA) for data cleaning and analysis.  
We will follow the Consolidated Standards of Reporting Trials (CONSORT) guidelines for reporting of 
clinical trials (http://www.consort-statement.org/).  
 
Analytical statistics  
The number and proportion of subjects who have treatment failures and ACPRs, as defined above, by day 28 
and 168 will be calculated.  We will also assess the potential risk factors (e.g., age, initial parasite density, 


 
 
8
etc.) for an association with the probability of a therapeutic failure and the time to therapeutic failure using 
Chi squared tests for dichotomous variables and Student’s t-tests for continuous variables.   
 
Proportion of P. vivax infections during follow-up will be evaluated.  We will determine the proportion of 
participants with ACPR in a per-protocol analysis approach, excluding participants with loss to follow-up, 
malaria infections other than P. vivax or withdrawal for other reasons.  We will compare these proportions 
between groups 1 and 3, and groups 2 and 3 using Pearson chi-square test for the per-protocol analysis.  We 
will repeat this analysis considering only homologous recurrences as failures.  
 
We will perform a survival analysis the Kaplan-Meier method, considering patients for as long as they stayed 
in the study.  Similarly, to the per-protocol analysis, we will stratify these curves by study group.  The log-
rank test will be used to compare survival times across treatment groups.  Cox proportional hazard regression 
will be used to evaluate potential confounders and effect modifiers (primaquine initiation date, G6PD 
activity, etc) on treatment efficacy response.   
 
A list of intended tables of anticipated descriptive and analytical tables is presented in Appendix B. 
Appendix C shows the Consort check list intended for use at time of report and manuscript writing.   
 
Adverse events  
Occurrence of side-effects and adverse events (AEs) associated with the study drugs or procedures will be 
monitored and recorded on an appropriate form. An AE is defined as treatment emergent if the first onset or 
worsening is after the first administration of study medication and not more than 7 days after the last 
administration of a study medication. AEs will be investigated and classified as associated or not with study 
participation. Patients with side-effects necessitating medical treatment or hospitalization will be referred for 
appropriate treatment.  Study participation may be discontinued if it is established that study procedures 
cannot be safely continued, such as study drug allergic events during treatment or G6PD deficiency, for that 
study participant.   
 
Number and frequency of AEs leading to withdrawal of study, by study group and specific medication or 
procedure associated with them, will be produced and reported. A data listing of AEs leading to withdrawal 


 
 
9
of study medication will also be provided, displaying details of the event(s) captured on the clinical reporting 
form.  
 
Patients with skin rash or any severe allergic reaction will be withdrawn from the study, while patients 
experiencing only itching will not be withdrawn from the study.  In addition, adverse events that are 
unexpected, likely related to the research study, and that place the participants at greater risk of harm will be 
reported to the local and CDC institutional review board in accordance with required reporting schedules 
after their occurrence, i. e., in no later than 2 working days of CDC awareness.   
 
Limitations  
Findings will be restricted to this region of Brazil and, until information from other parts of Brazil and the 
Amazon region can be collected, they should not be generalized. We will adopt a 6-month follow up period 
as an attempt to detect relapses, although relapses can occur up to 1 year or longer.  An even longer duration 
of follow-up is recommended to comprehensively estimate relapse rates in P. vivax studies.  However, longer 
studies would increase the likelihood of reinfections, and until methodological consensus exists on 
differentiating relapses from reinfection, we felt this would introduce undesired bias.  
 
Primaquine dosing will not be initiated at the same time for all participants due to variation in wait times for 
G6PD study results.  Ideally, we would like to administer primaquine at the same time for all patients in 
order to prevent differences in treatment of hypnozoites and, therefore, differential impact on the likelihood 
of relapse.  However, given our need to start primaquine as soon as possible and delays in G6PD 
determination, strict timing is not feasible.  
 
Our background information about the clonal variability of P. vivax microsatellite regions is derived from the 
variability of these regions in the 257 day 0 samples only. This approach may not detect alleles in lower 
frequency in the population. However, resource limitations do not allow for more accurate methods, such as 
deep sequencing, and chose to use microsatellite genotyping.   
 
There is no consensus on how to differentiate relapse and reinfection when recurrent P. vivax infection. Our 
analysis will focus on any P. vivax recurrence during follow up period.  We will, however, also determine 


 
 
10 
ACPR proportions considering only homologous recurrences since we believe those more directly relate to 
treatment response.   
 
References  
1. 
Lacerda MVG, Llanos-Cuentas A, Krudsood S, et al. Single-Dose Tafenoquine to Prevent Relapse of 
Plasmodium vivax Malaria. The New England journal of medicine 2019; 380(3): 215-28. 
2. 
Negreiros S, Farias S, Viana GM, et al. Efficacy of Chloroquine and Primaquine for the Treatment of 
Uncomplicated Plasmodium vivax Malaria in Cruzeiro do Sul, Brazil. Am J Trop Med Hyg 2016; 95(5): 
1061-8. 
3. 
WHO. Methods for Surveillance of Antimalarial Drug Efficacy; 2009. 
4. 
Beck HP, Wampfler R, Carter N, et al. Estimation of the Antirelapse Efficacy of Tafenoquine, Using 
Plasmodium vivax Genotyping. J Infect Dis 2016; 213(5): 794-9. 
 
 
 


 
 
11 
Appendix A. Randomization table  
 
 
Order 
Arm 
1 Grupo 3 
2 Grupo 3 
3 Grupo 2 
4 Grupo 1  
5 Grupo 2 
6 Grupo 3 
7 Grupo 1  
8 Grupo 3 
9 Grupo 2 
10 Grupo 2 
11 Grupo 1  
12 Grupo 3 
13 Grupo 1  
14 Grupo 3 
15 Grupo 1  
16 Grupo 2 
17 Grupo 2 
18 Grupo 3 
19 Grupo 3 
20 Grupo 1  
21 Grupo 2 
22 Grupo 2 
23 Grupo 3 
24 Grupo 3 
25 Grupo 2 
26 Grupo 1  
27 Grupo 2 
28 Grupo 3 
29 Grupo 2 
30 Grupo 3 
31 Grupo 1  
32 Grupo 2 
33 Grupo 1  
34 Grupo 3 
35 Grupo 3 
36 Grupo 2 
37 Grupo 2 
38 Grupo 2 
39 Grupo 3 
40 Grupo 2 
41 Grupo 3 
42 Grupo 1  
43 Grupo 3 
44 Grupo 1  
45 Grupo 3 
46 Grupo 2 
47 Grupo 2 
48 Grupo 2 
49 Grupo 3 
50 Grupo 1  
51 Grupo 3 
52 Grupo 1  
53 Grupo 2 
54 Grupo 2 
55 Grupo 3 
56 Grupo 1  
57 Grupo 2 
58 Grupo 3 
59 Grupo 3 
60 Grupo 3 
61 Grupo 2 
62 Grupo 1  
63 Grupo 2 
64 Grupo 2 
65 Grupo 3 
66 Grupo 1  
67 Grupo 3 
68 Grupo 2 
69 Grupo 2 
70 Grupo 2 
71 Grupo 3 
72 Grupo 1  
73 Grupo 3 
74 Grupo 1  
75 Grupo 2 
76 Grupo 3 
77 Grupo 3 
78 Grupo 2 
79 Grupo 3 
80 Grupo 3 
81 Grupo 2 
82 Grupo 1  
83 Grupo 2 
84 Grupo 1  
85 Grupo 1  
86 Grupo 2 
87 Grupo 2 
88 Grupo 3 
89 Grupo 3 
90 Grupo 1  
91 Grupo 1  
92 Grupo 2 
93 Grupo 3 
94 Grupo 2 
95 Grupo 3 
96 Grupo 2 
97 Grupo 1  
98 Grupo 3 
99 Grupo 3 
100 Grupo 2 
101 Grupo 1  
102 Grupo 3 
103 Grupo 3 
104 Grupo 2 
105 Grupo 2 
106 Grupo 1  
107 Grupo 1  
108 Grupo 2 
109 Grupo 3 
110 Grupo 2 
111 Grupo 3 
112 Grupo 3 
113 Grupo 2 
114 Grupo 1  
115 Grupo 1  
116 Grupo 3 
117 Grupo 2 
118 Grupo 3 
119 Grupo 1  
120 Grupo 2 
121 Grupo 2 
122 Grupo 3 


 
 
12 
123 Grupo 1  
124 Grupo 1  
125 Grupo 3 
126 Grupo 2 
127 Grupo 2 
128 Grupo 3 
129 Grupo 1  
130 Grupo 2 
131 Grupo 2 
132 Grupo 3 
133 Grupo 3 
134 Grupo 2 
135 Grupo 2 
136 Grupo 3 
137 Grupo 1  
138 Grupo 3 
139 Grupo 3 
140 Grupo 2 
141 Grupo 3 
142 Grupo 2 
143 Grupo 1  
144 Grupo 1  
145 Grupo 2 
146 Grupo 3 
147 Grupo 2 
148 Grupo 1  
149 Grupo 3 
150 Grupo 3 
151 Grupo 1  
152 Grupo 2 
153 Grupo 3 
154 Grupo 1  
155 Grupo 2 
156 Grupo 3 
157 Grupo 2 
158 Grupo 1  
159 Grupo 2 
160 Grupo 3 
161 Grupo 1  
162 Grupo 2 
163 Grupo 3 
164 Grupo 3 
165 Grupo 2 
166 Grupo 1  
167 Grupo 2 
168 Grupo 1  
169 Grupo 2 
170 Grupo 3 
171 Grupo 3 
172 Grupo 1  
173 Grupo 3 
174 Grupo 2 
175 Grupo 2 
176 Grupo 3 
177 Grupo 3 
178 Grupo 3 
179 Grupo 2 
180 Grupo 1  
181 Grupo 2 
182 Grupo 1  
183 Grupo 2 
184 Grupo 3 
185 Grupo 2 
186 Grupo 3 
187 Grupo 1  
188 Grupo 1  
189 Grupo 2 
190 Grupo 2 
191 Grupo 3 
192 Grupo 3 
193 Grupo 3 
194 Grupo 1  
195 Grupo 3 
196 Grupo 2 
197 Grupo 2 
198 Grupo 1  
199 Grupo 3 
200 Grupo 2 
201 Grupo 3 
202 Grupo 1  
203 Grupo 2 
204 Grupo 2 
205 Grupo 1  
206 Grupo 2 
207 Grupo 1  
208 Grupo 3 
209 Grupo 3 
210 Grupo 1  
211 Grupo 2 
212 Grupo 3 
213 Grupo 3 
214 Grupo 2 
215 Grupo 3 
216 Grupo 2 
217 Grupo 3 
218 Grupo 1  
219 Grupo 2 
220 Grupo 2 
221 Grupo 2 
222 Grupo 3 
223 Grupo 1  
224 Grupo 3 
225 Grupo 2 
226 Grupo 2 
227 Grupo 3 
228 Grupo 1  
229 Grupo 3 
230 Grupo 3 
231 Grupo 2 
232 Grupo 3 
233 Grupo 2 
234 Grupo 1  
235 Grupo 1  
236 Grupo 3 
237 Grupo 2 
238 Grupo 1  
239 Grupo 3 
240 Grupo 2 
241 Grupo 3 
242 Grupo 1  
243 Grupo 2 
244 Grupo 2 
245 Grupo 3 
246 Grupo 1  
247 Grupo 1  
248 Grupo 3 
249 Grupo 2 
250 Grupo 3 
251 Grupo 2 


 
 
13 
252 Grupo 1  
253 Grupo 1  
254 Grupo 2 
255 Grupo 3 
256 Grupo 2 
257 Grupo 3 
 


 
 
14 
Appendix B. List of anticipated tables and figures for data analysis.  
 
1. 
Study design and randomization into treatment groups.  
2. 
Participant’s characteristics at enrollment and during follow-up per study group, Cruzeiro do Sul, 
2018.  
3. 
Common symptoms at enrollment per study group.  
4. 
Asexual parasite density clearance per study day per study group.  
5. 
Participant’s outcome in the per-protocol analysis per study group at day 28 and day 168, Cruzeiro do 
Sul, 2018. 
6. 
Haplotypes classification of paired samples Plasmodium vivax recurrences with valid microsatellite 
results, Cruzeiro do Sul, 2018.  
7. 
Participant’s CYP2D6 metabolic phenotypes profiles correlated with Plasmodium vivax recurrences, 
Cruzeiro do Sul, 2018. 
8. 
Cox regression model for freedom from recurrence at day 168, Cruzeiro do Sul. 
9. 
Geometric mean of asexual parasitemia of Plasmodium vivax among participants per treatment group 
during first 28 days of follow-up, Cruzeiro do Sul, 2018.  
 
 


 
 
15 
Appendix C. CONSORT checklist of information to include when reporting a trial   
 
Section/Topic 
Item 
No 
Checklist item 
Reported on 
page No 
Title and abstract 
 
1a 
Identification as a randomised trial in the title 
 
1b 
Structured summary of trial design, methods, results, and conclusions (for specific 
guidance see CONSORT for abstracts) 
 
Introduction 
Background and 
objectives 
2a 
Scientific background and explanation of rationale 
 
2b 
Specific objectives or hypotheses 
 
Methods 
Trial design 
3a 
Description of trial design (such as parallel, factorial) including allocation ratio 
 
3b 
Important changes to methods after trial commencement (such as eligibility criteria), 
with reasons 
 
Participants 
4a 
Eligibility criteria for participants 
 
4b 
Settings and locations where the data were collected 
 
Interventions 
5 
The interventions for each group with sufficient details to allow replication, including 
how and when they were actually administered 
 
Outcomes 
6a 
Completely defined pre-specified primary and secondary outcome measures, 
including how and when they were assessed 
 
6b 
Any changes to trial outcomes after the trial commenced, with reasons 
 
Sample size 
7a 
How sample size was determined 
 
7b 
When applicable, explanation of any interim analyses and stopping guidelines 
 
 
 
 


 
 
16 
Randomisation: 
 
 
 
 Sequence 
generation 
8a 
Method used to generate the random allocation sequence 
 
8b 
Type of randomisation; details of any restriction (such as blocking and block size) 
 
 Allocation 
concealment 
mechanism 
9 
Mechanism used to implement the random allocation sequence (such as sequentially 
numbered containers), describing any steps taken to conceal the sequence until 
interventions were assigned 
 
 Implementation 
10 
Who generated the random allocation sequence, who enrolled participants, and who 
assigned participants to interventions 
 
Blinding 
11a 
If done, who was blinded after assignment to interventions (for example, 
participants, care providers, those assessing outcomes) and how 
 
11b 
If relevant, description of the similarity of interventions 
 
Statistical methods 
12a 
Statistical methods used to compare groups for primary and secondary outcomes 
 
12b 
Methods for additional analyses, such as subgroup analyses and adjusted analyses 
 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a 
For each group, the numbers of participants who were randomly assigned, received 
intended treatment, and were analysed for the primary outcome 
 
13b 
For each group, losses and exclusions after randomisation, together with reasons 
 
Recruitment 
14a 
Dates defining the periods of recruitment and follow-up 
 
14b 
Why the trial ended or was stopped 
 
Baseline data 
15 
A table showing baseline demographic and clinical characteristics for each group 
 
Numbers analysed 
16 
For each group, number of participants (denominator) included in each analysis and 
whether the analysis was by original assigned groups 
 
Outcomes and 
estimation 
17a 
For each primary and secondary outcome, results for each group, and the estimated 
effect size and its precision (such as 95% confidence interval) 
 
17b 
For binary outcomes, presentation of both absolute and relative effect sizes is 
recommended 
 
Ancillary analyses 
18 
Results of any other analyses performed, including subgroup analyses and adjusted 
analyses, distinguishing pre-specified from exploratory 
 
Harms 
19 
All important harms or unintended effects in each group (for specific guidance see 
CONSORT for harms) 
 
 


 
 
17 
Discussion 
Limitations 
20 
Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, 
multiplicity of analyses 
 
Generalisability 
21 
Generalisability (external validity, applicability) of the trial findings 
 
Interpretation 
22 
Interpretation consistent with results, balancing benefits and harms, and considering 
other relevant evidence 
 
Other information 
 
Registration 
23 
Registration number and name of trial registry 
 
Protocol 
24 
Where the full trial protocol can be accessed, if available 
 
Funding 
25 
Sources of funding and other support (such as supply of drugs), role of funders 
 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important 
clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and 
equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those 
and for up to date references relevant to this checklist, see www.consort-statement.org. 


 
 
1